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ABSTRACT 
 
Targeting of specific developmental pathways to understand dendritic cell  
heterogeneity and function 
Kanako L.T. Lewis 
 
Dendritic cells (DC) are cells of the immune system that are specialized in sensing and 
responding to pathogens. They coordinate innate and adaptive immune responses to different 
types of pathogens through the release of inflammatory cytokines, secretion of interferon, and 
presentation of antigen to naïve T cells. Several different subsets of dendritic cells have been 
distinguished in the spleen and intestine based on their ability to perform these different functions. 
However, the specific signaling pathways and transcription factors involved in DC subset 
differentiation and the precise functions of these subsets are not well understood. Plasmacytoid 
dendritic cells (PDCs) are a subset of dendritic cells that are specialized at the secretion of type I 
interferon. Through conditional targeting of E2-2, a transcription factor essential for the 
specification of the PDC lineage, we have demonstrated a vital role for PDCs in the control of 
acute and chronic viral infections. In addition, deletion of E2-2 was employed to characterize 
novel E2-2-dependent, alternative CD8+ DC fates. Furthermore, we have identified a common 
pathway for the differentiation of the key T cell-priming populations of CD11b+ DCs in the spleen 
and intestine. Specific targeting of Notch2 revealed that splenic CD11b+ DCs are comprised of at 
least two functionally and developmentally distinct populations that can be distinguished by their 
expression of the surface molecule Esam. Deletion of Notch2 in dendritic cells also led to the 
specific loss of CD103+CD11b+ DCs from the lamina propria of the intestine and a corresponding 
reduction in IL-17-producing T cells. Throughout these studies, the identification of specific 
developmental pathways of DC subsets has provided key insights into their different functions. 
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Dendritic cells (DCs) are pathogen-sensing cells that are specialized in initiating the 
adaptive immune response. As key sentinel cells, DCs can be found throughout body and are 
tailored to survey a variety of tissues including environmental interfaces such as the skin or 
intestine, filtering organs, and lymphoid organs. Like macrophages, DCs continuously sample 
their environment, but unlike macrophages, DCs migrate to local lymph nodes where they 
efficiently present processed antigen to T cells. Dendritic cells were first described in 1868 by 
Paul Langerhans who observed neuron-like cells in the epidermis of the skin. In 1976, over a 
century later, Ralph Steinman and Zanvil Cohn identified the specialized function of these cells in 
stimulating T cells and named them “dendritic cells” after their prominent branching projections (1, 
2). These extensions maximize their surface area and thus their contact with the environment. DC 
processes can also penetrate through tissues, expanding their reach into sites such as the lumen 
of the gut. The Cohn and Steinman groups also defined DCs phenotypically as cells with high 
levels of MHC class II molecules (3) and the integrin CD11c (Itgax) (4).  
DCs are well adapted to sense a variety of pathogen-associated molecular patterns 
(PAMPs). They express different receptors that can sense intracellular and extracellular 
pathogens, including toll-like receptors (TLRs), lectins, and cytoplasmic sensors such as RigI-like 
helicases (RLHs) and Nod-like receptors (NLRs). Most TLRs are expressed on the cell surface, 
and respond to extracellular stimuli such as LPS and flagellin. TLR3, TLR7/8, and TLR9 are 
expressed in endosomes and detect pathogen-associated nucleic acid signatures. RLHs and 
NLRs are intracellular receptors that can sense PAMPs within the cytosol. Stimulation of these 
pattern recognition receptors (PRRs) can trigger the type I interferon (IFN) response, 
inflammasome induction, activation of the NF-κB pathway, and secretion of inflammatory 
cytokines.  
Activation of DCs leads to the upregulation of MHC class II and co-stimulatory molecules 
and migration to the T cell zone of lymphoid tissue, where they perform several functions. Mature 
DCs present antigen and express the co-stimulatory molecules necessary to activate naïve T 
cells, the initiating event in the adaptive immune response. DCs also secrete cytokines that direct 
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T cell responses and stimulate other effector cells. Finally, DCs secrete type I IFN, which 
activates a signaling cascade that promotes both the innate and adaptive arms of the immune 
response. In addition to activating specific immune cells, IFNα/β also induces the upregulation of 
MHC class I and promotes the expression of antiviral genes, such as Mx1. DCs are broadly 
categorized by their ability to perform these three functions. Conventional DCs (cDCs) are 
effective at the classical functions of dendritic cells, including antigen presentation and T cell 
stimulation, while plasmacytoid DCs (PDCs) are especially equipped for the secretion of type I 
IFN.  
                      
Figure 1. The development of dendritic cells.  
 
DC development 
Despite their central role in activating immune responses, the development and 
differentiation of DCs remain areas clouded by controversy and confusion. DC development 
begins in the bone marrow from hematopoietic stem cells (HSCs) (Fig. 1). HSCs are thought to 
give rise to common progenitors of monocytes and DCs (MDPs). It should be noted, however, 
that without definitive clonogenic evidence of their existence, the true nature of the MDP 









population remains controversial. DCs develop readily from monocytes under inflammatory 
conditions, but most steady-state DCs do not differentiate from monocytes, arising instead from a 
common DC/PDC precursor (CDP) in a Flt3-dependent manner (5-7). PDC development from 
CDPs continues in the bone marrow, but the further differentiation of cDCs from committed cDC 
precursors (preDCs) occurs in the periphery (7). In the spleen, preDCs give rise to two 
populations of cDCs: CD11b+ (CD8-), or “myeloid” DCs, which represent the majority of DCs in 
the spleen, and CD8+ DCs.  
 
Differentiation of splenic DC subsets 
The development of CD11b+ DCs depends on several factors, including IRF4 (8), IRF2 
(9), and RBP-J (10) (Table 1). However, none of these transcription factors are absolutely 
required for CD11b+ DC development since deletion of each causes only partial loss of CD11b+ 
DCs. RelB has also been reported as a selective regulator of the myeloid DC lineage, but it 
remains unclear if RelB deletion leads to a consistent or significant decline in CD11b+ DCs: RelB 
also leads to widespread inflammation and hyperplasia (11). In addition to transcription factors, 
signaling through lymphotoxinβ has been implicated as a cell-intrinsic regulator of the 
homeostasis of myeloid DC cells in the spleen (12, 13). Despite the identification of many 
potential regulators of CD11b+ DCs, the signaling pathways and transcription factors that dictate 
CD11b+ DC differentiation in the spleen and other organs are not well understood. Importantly, a 
factor or pathway solely responsible for CD11b+ DC development has yet to be identified.  
The development of CD8+ DCs has been shown to be dependent on the transcription 
factor Batf3 (14). However, a small proportion of CD8+ DCs appear to be regulated independently 
of Batf3 (15). Id2 (16) and IRF8 (17) also contribute to CD8+ DC formation. PDC development 
also depends on IRF8.  However, contrary to frequently reiterated reports, PDC development is 
not affected by the deletion of either Id2 (16) or Irf4 (8). Ikaros is another potential regulator of 
PDC differentiation. Ikaros hypomorphs (IkarosL/L) exhibit severe PDC depletion without loss of 
cDCs (18). SpiB has also been suggested to be important for human PDC development, but its 
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role has not yet been demonstrated in an animal model (19). Finally, our lab has shown that E2-2 
is specifically and absolutely required for PDC development (20). The identification of Batf3 and 
E2-2 as regulators of the development of DC lineages has helped not only to determine how DC 
subsets differentiate, but also to uncover their distinct functions.  
 
 PDC CD8+ DC CD11b+ DC 
E2-2  (20) O -- -- 
IkarosL/L  (18) O -- -- 
Batf3  (14) -- O -- 
Id2  (14) --  -- 
Irf8  (17)   -- 
Irf4  (8, 21) -- --  
RelB  (11)  --  
Irf2  (9)  --  
 
Table 1. Dendritic cell phenotypes in transcription factor knockout mice. 
Elimination or near elimination (O), reduction (), or no change (--) in the cell 
populations of knockout mice are indicated.  
 
The function of DC subsets 
The identification of Batf3 as a specific regulator of CD8+ DCs has helped to support a 
distinct role for CD8+ DCs in cross-presentation, a process where exogenous antigen is 
presented on MHC class I. Cross-presentation is thought to play a vital role in CTL activation 
during viral infection and tumor surveillance (22). In comparison, the lack of insight into the 
specific pathways of CD11b+ DC development has hindered examination of their functional 
relevance.  Although they are believed to be proficient at the presentation of antigen on MHC 
class II molecules (23), surprisingly little evidence has been presented to support this assumption 
or conclusively demonstrated their relevance in infections. The role of PDCs in the response to 
acute viral infection has also not been clearly documented. In addition, the precise role of PDCs 
during chronic viral infection has never been examined. 
Significant advances in understanding how DCs function in general have been made 
through studies of nonlymphoid DCs. In the intestine, three classical DC subsets have been 
identified: CD103+CD11b- and CD11b+CD103+ DCs, which arise from preDCs, and 
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CD11b+CD103- DCs that originate in the steady-state from monocytes or monocyte precursors 
(24). CD103+CD11b- DCs of the lung and intestine do not selectively express CD8, but have been 
suggested to represent CD8+ DC counterparts in nonlymphoid tissues because of their ability to 
prime CD8+ T cells, similar genetic profile, and shared dependence on Batf3 (25). The 
identification of Batf3 as a common and specific regulator of CD103+CD11b- and CD8+ DC 
underscores the relationship between the two subsets, and also presents a tool for definitive 
studies of their function. Although their role in the intestine is still unclear, they may engage in 
cross-presentation of antigen like their splenic CD8+ DC counterparts  
CD11b+ CD103- intestinal DCs are able to sample the contents of the gut by extending 
dendritic processes into the intestinal lumen, but do not migrate from the intestine to the MLN.  
Instead, this task is performed by CD11b+CD103+ DCs, the primary migrating and antigen-
presenting subset of CD11b+ DCs in the intestine. Therefore, in contrast with the single CD11b+ 
DC population that exists in the spleen, there is an apparent division of labor between two distinct 
CD11b+ DC populations in the gut. The relationship between these subsets and the specific 
factors and signaling pathways involved in their differentiation in the spleen and intestine remain 
unknown.  
The overall aim of the following work is to identify and target specific transcription factors 
and signaling pathways necessary for the development of DC subsets in order to understand their 
function. In Chapter 1, a known PDC-specifying transcription factor, E2-2, is used to target PDCs 
and define their function within the context of acute and chronic viral infections. In Chapter 2, the 
role of E2-2 in the maintenance of PDCs is demonstrated through the examination of an 
alternative CD8+ DC population. In addition, a Batf3-independent alternative CD8+ DC fate and its 
dependence on E2-2 is characterized in Chapter 2. Finally, Notch2 signaling is identified as a 
common pathway necessary for the development of CD11b+ DC subsets in the spleen and 
intestine in Chapter 3. Abrogation of Notch2 signaling also elucidates the relationship between 
these subsets and their function. Throughout these studies, the divergence, plasticity, and 














Analysis of PDC function through the generation of mice that  





Plasmacytoid dendritic cells (PDCs) are specialized DCs that are capable of producing 
high levels of type I interferon (IFN) in response to viral infection (26, 27). Their discovery in 1999 
as low frequency cells in human blood resolved two long-standing mysteries: the function of 
plasma cell-like cells that had been first observed in the T cell zones of human lymphoid tissues 
(28) and the cellular source of the “natural” interferon response to viruses (29). By 2001, several 
groups confirmed the identity of PDCs in mice, leading to their definitive description as unique 
type I IFN-producing cells (30-32). Although many cells can secrete interferons during infection, 
PDCs are unique in their rapid and vigorous response to viruses and other pathogens. PDCs 
express endosomal toll-like receptors (TLRs) that sense signature patterns of pathogen-
associated nucleic acids: TLR7/8, which recognizes G/U-rich single-stranded RNA and TLR9, 
which detects unmethylated CpG-containing single-stranded DNA. Rather than rapidly degrade 
these ligands, PDCs retain them in endosomal compartments, prolonging their signaling potential 
(33). PDCs also constitutively express elevated levels of IRF7, a critical signaling intermediate of 
type I IFN induction (34). This allows PDCs to respond more rapidly than other cells to TLR 
stimulation. To produce large amounts of IFN, PDC have increased endoplasmic reticulum (ER), 
adopting a morphology similar to plasma cells, which also produce large amounts of protein in the 
form of antibodies.  
The classification of PDCs as dendritic cells was initially proposed because of their ability 
to acquire a DC-like morphology and stimulate naïve T cell proliferation after maturation with IL-3 
and CD40L (35). Thus, PDCs were suggested to be precursors of DCs. However, very little 
evidence has been presented to suggest that mature PDCs function significantly as antigen-
presenting cells in vivo. Though PDCs and cDC arise from a common precursor (CDP) and both 
are dependent on Flt3L signaling, PDCs develop fully in the bone marrow (Fig. 2) and possess 
several characteristics that suggest considerable divergence from conventional DCs. In addition 
to their distinct morphology, high IFNα/β-secreting capacity, and poor antigen-presenting ability, a 
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unique feature of the PDC lineage is their expression of genes normally restricted to early 
lymphoid development, including Dntt (Tdt), VpreB, PTCRA (pre-Tα) and Rag1/2. A fraction of 
PDCs even harbor IgH D-J rearrangements, which was initially considered evidence that PDCs 
arise through the lymphoid lineage (36). More recently, this peculiar genetic program has been 
linked to their dependence on E2-2, an E protein specifically required for PDC development. 
 
Figure 2. PDCs develop fully in the bone marrow. PDCs and cDCs are 
generated through a common pathway that begins with the differentiation of a 
multipotent progenitor (MDP) from hematopoietic stem cells (HSC). MDPs then 
give rise to a common DC/PDC precursor (CDP). PDC development continues in 
the bone marrow through an E2-2 dependent manner, while cDCs arise from pre-




E proteins are a family of E-box (CANNTG) binding, basic helix-loop-helix (bHLH) 
transcription factors that include E2A, HEB and E2-2. They are known to have specific roles 
during lymphopoiesis, particularly in regulating immunoglobulin and T cell receptor expression. 
E2A (Tcf3), which encodes E12 and E47 splice variants (37), is essential for B cell development 
and the induction of RAG1/2 (38). Heterodimers of E2A proteins and HEB are required for T cell 
receptor rearrangement and development of αβ T cells in the thymus (39). The activity of E 
proteins is counterbalanced by the expression of inhibitor of DNA-binding (Id) proteins. Id proteins 
form heterodimeric complexes with E proteins through their conserved bHLH regions, but lack 
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DNA-binding domains, preventing the formation of active E protein dimers. In turn, Id proteins are 
involved in governing non-PDC cell fates, including NK cells (40), CD8+ DCs and Langerhans 
cells (LCs) (16), at least in part, through the suppression of E protein-driven lymphoid programs 
(Fig. 3).  
 
                                                         Adapted from Reizis, Curr Opin Immunol (41) 
 
Figure 3. E proteins function as homo- or heterodimers. The E proteins, E2A, 
HEB, and E2-2, form homodimers or heterodimeric complexes with other E or Id 
proteins through interaction between their helix-loop-helix structures. Id proteins 
lack DNA-binding domains, which prevents Id-containing complexes from binding 
to E box sequences. Transcriptional regulation by E2A homodimers and 
E2A/HEB heterodimers are essential for B and T cell development, respectively. 
As the sole E protein required for PDC development and maintenance, E2-2 
presumably functions as a homodimer. E2-2 directly regulates many PDC-
specific genes in mice and humans, including Irf7, BDCA2, and ILT7. E2-2 also 
directs expression of genes such as Dntt, Ccr9, PTCRA, and CIITA pIII that are 
targets of other E protein family members during in lymphoid cells.  
 
Without a clear role in lymphopoiesis, E2-2 has long been considered an outlier in the E 
protein family. E2-2, encoded by Tcf4, is expressed at low levels in B cells, but is largely 
dispensable for the development of both B and T cells (20). In contrast to E2A and HEB, E2-2 is  
highly expressed in the brains of both humans and mice. Monoallelic loss-of-function mutations or 


















Dntt, Ccr9, PTCRA 
CIITA pIII 
Irf7, BDCA2, ILT7 
Adapted from Reizis (2010) 
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retardation, breathing irregularities and craniofacial abnormalities (42, 43). Mutations within Tcf4-
containing loci has also been associated with schizophrenia (44, 45) and corneal dystrophy (46) 
in humans. E2-2 knockout mice die at birth, but E2-2 heterozygotic mice display no overt 
abnormalities (47).  
In 2008, our lab identified E2-2 as a specific and essential regulator of the PDC lineage. 
E2-2 deletion in mice resulted in complete loss of PDCs without affecting the development of any 
other hematopoietic lineage (20). Haploinsufficiency of E2-2 resulted in a two-fold reduction in 
PDC numbers and impaired IFN response in both mice and PHS patients. Analysis of its targets 
in PDCs has demonstrated that E2-2 regulates the expression of both PDC-specific genes, 
including Irf7, BDCA2, and ILT7, and lymphoid-specific genes, such as CIITA pIII, Dntt, and 
PTCRA. This discovery has not only assigned a role for E2-2 in directing an immune cell fate, but 
has also explained why PDCs share expression of genes that are associated with the lymphoid 
lineage (41). 
 
The role of PDCs in viral infection 
Although PDC are considered to be specialists in the secretion of type I IFN in response 
to viruses, many fundamental questions remain about their role in viral infections. It is unclear 
how uniquely important they are for the control of viral infections, how universal their role is in the 
defense against different pathogens, and if PDC-mediated antigen presentation and T cell 
priming influence the outcome of infections. To address these questions, several key virus 
models have been employed, including mouse hepatitis virus (MHV), mouse cytomegalovirus 
(MCMV), and lymphocytic choriomeningitis virus (LCMV).  
MHV is a cytopathic single-stranded RNA virus that commonly afflicts laboratory mouse 
colonies and, as a coronavirus, resembles SARS-CoV and viruses that cause the common cold in 
humans. MHV is an example of a virus whose clearance depends on PDC-derived type I IFN 
(48). Acute MHV infection induces a rapid burst of type I IFN secretion that is essential for 
survival as IFNAR knockouts succumb to MHV with rampant viral spread within two days of 
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infection (48). Importantly, Cervantes-Barragan et al. demonstrated that PDC depletion prevents 
this robust early type I IFN response and permits viral spread. Clearance of RSV, which causes a 
similar acute infection, has also been shown to be dependent on PDC-derived type I IFN (49, 50). 
Therefore, PDCs are essential for the early IFNα/β response to and clearance of some viruses.  
The role of PDCs during other viral infections, such as MCMV, is less clear. MCMV is an 
enveloped double-stranded DNA virus of the herpes family that is commonly used to model 
human cytomegalovirus (CMV). PDCs are required for peak IFNα response (31) and to control 
replication during the first days of MCMV infection (51-53). However, the resolution of MCMV 
infection depends primarily on the activation of NK cells, which may be facilitated by, but does not 
require PDCs (52, 54). In fact, IFNα production through IRF7 appears to be dispensable for 
inducing NK cell activity and contributes little to overall survival of infected animals (55). VSV, 
influenza, and HSV also stimulate IFNα secretion from PDC, but it is uncertain if these responses 
elicit protection against these viruses due to difficulties in discriminating the effects of PDCs from 
other cell types (56, 57).  
LCMV is a single-stranded RNA arenavirus that has been instrumental in the study of 
acute and chronic infections. LCMV normally causes a chronic infection in rodents, but can be 
manipulated experimentally to elicit defined immune responses, depending on the dose or strain 
employed. The LCMV Armstrong strain (LCMV-Arm) causes an acute infection that induces early 
and prominent type I IFN production (58, 59) that does not depend on PDC activity (51, 53). 
Another acute strain of LCMV, LCMV-WE, similarly induces an early IFN response (60). The 
production of other cytokines and the CTL response that ultimately eradicate LCMV-Arm are also 
unaffected by PDC depletion, indicating that PDCs are not required for resolving acute LCMV 
infections (53).  
LCMV Clone 13 (LCMV Cl. 13) is a variant of LCMV-ARM that can manifest as a chronic 
infection. LCMV Cl. 13 also induces high levels of IFNα several days after infection (58, 59), but 
unlike LCMV-Arm, Cl. 13 is able to persist in the kidneys of infected mice (61). Interestingly, the 
type I IFN response is dampened during secondary viral infections several weeks after initial 
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infection, indicating that LCMV Cl. 13 suppresses the IFN response and that this modulation may 
aid in its persistence (56, 59). High dose infection with LCMV Cl. 13, or the similar LCMV-WE 
variant, LCMV-DOCILE, can lead to an impaired T cell response termed “T cell exhaustion,” 
which represents both activation-induced depletion of T cells and impaired T cell function due to 
viral persistence (62). A hallmark of T cell exhaustion is the upregulation of inhibitory receptors, 
including programmed death 1 (PD-1) (63). Some non-cytopathic viruses are thought to exploit T 
cell exhaustion to establish life-long persistence. These viruses have a rapid initial replication rate 
that outpaces T cell expansion, permitting spread to target reservoirs, where they persist at low 
levels. Indeed, comparison of LCMV Cl. 13 and LCMV-Arm confirms that a point mutation in the 
Cl. 13 polymerase that causes a faster replication rate is a primary determinant in its ability to 
persist and induce T cell exhaustion (64). Studies using LCMV Cl. 13 and DOCILE have begun to 
elucidate the role of T cell exhaustion in viral persistence and pathology associated with chronic 
infections, such as hepatitis C and HIV.  
It is unknown if PDC activity is modulated by chronic LCMV or if PDCs function 
significantly during chronic viral infections. Of particular interest is whether PDC play a role in T 
cell exhaustion and if they promote T cell responses exclusively through cytokine secretion. DCs 
are classically defined by their ability to present antigen and stimulate T cell proliferation, but 
PDCs have been described as poor stimulators of T cell proliferation that can be coaxed to 
promote antigen-specific CD4 and CD8 T proliferation after stimulation (31, 52). On the other 
hand, PDCs have been shown to be important in stimulating lymph node DCs, thereby indirectly 
promoting anti-viral CD8+ T cell responses after cutaneous infection with herpes simplex virus 
(65). However, further investigation is necessary to determine how PDC function during viral 
infections.  
 
The role of PDC in autoimmune diseases 
In addition to their role in normal immune responses, PDCs may also play a role in the 
induction and progression of several autoimmune diseases, including multiple sclerosis (MS), 
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asthma, lupus, and psoriasis.  Genome-wide association studies have linked a TCF4-containing 
locus (18q21) with several autoimmune diseases, which hints that TCF4 may be an autoimmune 
susceptibility gene. PDCs, along with cDCs, infiltrate the CNS during acute relapsing 
experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, which has led to 
speculation that PDCs influence EAE disease outcomes(66). Depletion of PDCs after EAE 
induction exacerbates the disease, but has no significant effect on CD4+ or regulatory T cell 
responses (67, 68). Furthermore, CNS-infiltrating PDCs induce little naïve T cell expansion in 
vitro, in comparison to cDCs (66). In contrast, PDC depletion prior to EAE induction reduces the 
severity of EAE (68), suggesting that PDC may play a role in the induction of EAE while inhibiting 
the progression of the disease once it is initiated. Finally, a recent study has suggested that PDC-
mediated antigen presentation is necessary to prevent the autoimmune T cell response after EAE 
induction (69). Further study is necessary to clarify these potential roles and determine if PDC are 
involved in EAE.  
It has also been suggested that PDCs help to control the development of asthma. PDC 
depletion leads to the development of key symptoms of asthma in mice after inhalation of 
ovalbumin (OVA), which is normally non-immunogenic (70). This indicates that PDCs help to 
control the sensitization to inhaled antigen. In addition, expansion of PDCs through Flt3L 
treatment (71) or adoptive transfer of PDCs (70) reduces several disease features after asthma 
induction. However, non-PDCs may upregulate expression of Bst2 after induction of airway 
hyper-responsiveness to allergens (72), which complicates PDC identification and targeting in the 
lung. Furthermore, expansion of PDCs using Flt3L and adoptive transfer may alter their normal 
circulation and functional capacity. Therefore, it remains unclear if and how PDC regulate 
tolerance to inhaled antigen in an unperturbed system.  
Studies in human patients with SLE have indicated that chronic activation of PDC is a 
major contributor to lupus pathogenesis. In particular, as major type I IFN producers, PDCs have 
been speculated to be the source of the elevated levels of IFNα found in many human patient 
sera. A recent study has suggested that neutrophils from SLE patients release elevated levels of 
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neutrophil extracellular traps (NETs), which are web-like structures of self-nucleic acid (73). NETs 
can effectively activate PDCs, suggesting a potential link between NETs in the chronic activation 
of PDCs in SLE. However, there is conflicting evidence regarding the role of type I IFN in mouse 
models of SLE. IFNAR1 deficiency prevents disease in some lupus models (74), but causes 
exacerbated disease in congenic lupus-prone MRL/lpr mice (75). The specific role of PDCs in the 
type I IFN response in these models is even less clear.  
A number of studies have led to implication of PDCs in the initiation of psoriasis. Elevated 
type I IFN levels and PDC accumulation have been detected in human psoriatic lesions, while 
blocking of type I IFN signaling or suppression of PDC-mediated IFNα/β production inhibits the 
development of disease in human xenograft models of psoriatic skin (76). LL37, an antimicrobial 
peptide that is highly expressed in psoriatic lesions, has been shown to convert self-DNA or self-
RNA into immunogenic complexes that are sensed by PDCs via TLR9 or TLR7, respectively (77, 
78). A current model for the development of psoriasis places PDCs as the initial immune cells that 
detect these aberrant nucleic acid complexes and initiate a cycle of autoimmune T cell activation 
through the secretion of type I interferon (79).  
 
PDCs in tolerance and cancer 
A limited number of studies have suggested that PDCs induce tolerance to transplant and 
dietary antigens. PDCs purportedly induce regulatory T cells, inhibit acute graft-versus-host 
disease (80) and enhance tolerance to vascularized grafts (81). In addition, PDC depletion 
appears to increase the contact hypersensitivity response to hapten challenge after oral priming, 
indicating that PDCs may also mediate oral tolerance (82). However, additional evidence is 
necessary to support the notion that PDCs play a significant role in the induction of tolerance.  
Interferon-α is a powerful anti-tumor therapeutic that has been used to treat a variety of 
hematological malignancies and solid tumors. Given the importance of PDCs in producing IFNα, 
it is not surprising that PDCs have been linked to the immune response to tumors. In fact, PDCs 
have been found to accumulate in many tumors, including ovarian tumors (83), melanoma (84), 
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and head and neck cancers (85). However, this accumulation has been associated with the 
inhibition of PDC function, suggesting that tumors may actively recruit PDCs in order to suppress 
their function. In support of this notion, PDC infiltration of breast tumors has been correlated with 
poor prognosis (86). Therefore, understanding the potentially protective versus subverted roles of 
PDCs in cancer may be important for therapeutic advances.  
 
Tools to study PDC function 
Many challenges have hindered the understanding of PDC function in infection, 
autoimmunity, tolerance, and cancer. Initial characterizations lacked distinguishing markers to 
identify PDCs, while current studies have been confounded by variation in the expression of 
these markers in different organs and disease states. Additionally, steady-state PDC numbers 
and reactivity vary considerably by strain (51), which limits the study of diseases that are modeled 
on specific mouse strains. Finally, the lack of a method of complete and specific PDC depletion 
has made confirmation of the PDC functions in vivo particularly difficult.  
PDC depletion methods have been limited in their ability to specifically, completely, and 
permanently target PDCs. Initial studies used anti-Gr1 antibody to take advantage of the high 
expression of Ly6C on murine PDCs (87). This method was instrumental in the initial identification 
of PDCs in mice and for determining their functional relevance during viral infection (31). 
However, this approach does not completely eliminate PDC and depletes additional cells, 
including neutrophils, monocytes, macrophages, and activated T cells. Depletion using the PDC-
specific antibody, Bst2, specifically reduces PDCs by approximately 80 percent and effectively 
eliminates the IFNα response to CpGs (87). This approach was used to show that intact PDCs 
are necessary for a robust serum IFNα response to MCMV (52) and to control MHV infection 
(48). However, its applications are limited since Bst2 is upregulated in non-PDCs in tumors 
certain disease states, and because antibody-mediated depletion is transient and incomplete for 
PDC.  
Alternatively, transgenic expression of diphtheria toxin receptor (DTR) or STOP-floxed 
diphtheria toxin (DTA) has been used to target specific cell populations upon administration of 
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diphtheria toxin. CD11c-Cre DTA mice have been used to successfully ablate conventional DCs 
(88). Targeting PDCs through these approaches has been less successful as PDCs express an 
intermediate level of CD11c (88). Recently, the Colonna lab has generated mice that express 
BDCA-2-DTR, which effectively reduces PDC levels and CpG-induced serum IFNα upon 
diphtheria toxin treatment (53). However, as with all DTR-mediated systems, repeated 
administration of diphtheria toxin is necessary to maintain cell depletion, leading to considerable 
toxic side effects. 
Genetic models that constitutively lack PDCs are essential for definitive and long-term 
studies of PDC functions. Historically, studying PDCs has relied on tools that non-specifically 
target PDC development (i.e. IkarosL/L), impair the PDC response to stimuli (i.e. TLR and adaptor 
knockouts) or target the downstream effects of PDC-derived type I IFN (i.e. IFNAR knockouts). 
The importance of type I IFN in controlling viral infection has been highlighted in several studies 
showing increased MCMV load (51) and increased susceptibility to MHV (48) using IFNAR 
knockouts. Conditional deletion of IFNAR using cell-specific Cre animals has also been useful in 
determining the precise targets of type I IFN responses (89). However, the development of 
genetic approaches that deplete PDCs specifically and without toxicity is important for 
understanding the function of PDCs and essential for the study of long-term and chronic disease 
states. Here, we have generated a mouse that constitutively lacks PDCs through the conditional 





Generation of PDC-less mice 
  Conditional targeting of E2-2 in CD11c-positive cells (E2-2fl/fl CD11c-Cre+) led to 
incomplete PDC depletion in B6 mice. Therefore, mice with complete peripheral PDC depletion 
were generated by crossing Sv129 E2-2 heterozygous (E2-2+/-) animals to mice with dendritic 
cell-specific deletion of E2-2 (E2-2fl/fl CD11c-Cre+), generating conditional knockout animals 
(CKO) with one LoxP-flanked allele and one germline-deleted allele of E2-2 (E2-2fl/- CD11c-Cre+) 
on a defined B6129F1 background. This approach took advantage of both the underlying E2-2 
heterozygosity and difference in strain background to improve targeting efficiency. Importantly, 
E2-2 heterozygosity has been previously demonstrated to not affect the development of any other 
cell population (20). Splenic PDCs were significantly absent in cell fraction and absolute numbers 
in CKO animals (Fig. 4A, 4C), while splenic cDCs were unaffected (Fig. 4B, 4C). PDCs were also 
absent from all organs investigated, including lymph nodes (LN), thymus, lung, liver, and small 
intestine (Fig. 4C, 5, 15). B220+CD8+ cDC-like cells arising from peripheral E2-2 deficient PDCs 
were not reliably observed in CKO mice. The relative increase in cDC fraction in the CKO was 
statistically significant, but total cDC numbers were unaffected. PDCs were reduced 
approximately two-fold in the bone marrow. The residual PDCs expressed lower level of CDllc, 
indicating that they may represent immature PDCs. Remaining bone marrow PDCs secreted 
IFNα in response to unmethylated CpG-containing DNA (CpG), but notably did not contribute to 
systemic IFNα secretion as measured by the absence of IFNα induction in the serum of CpG 
injected mice.  These data indicate that E2-2-deficient PDCs were either not maintained or 
ineffective in the periphery (Fig. 6A, 6B).  
  The specificity of targeted deletion was measured by expression of a Cre-inducible YFP 
reporter in CKO animals (Gt(ROSA)26Sor-EYFP+ E2-2fl/- CD11c-Cre+). Evidence of Cre-mediated 
recombination was prominent in conventional DCs, as expected (Fig. 7B). Other cell populations, 
such as NK cells, exhibited partial recombination, while a negligible amount of recombination 
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occurred in B cells, the only cell population other than PDCs that expresses significant levels of 
E2-2 (Fig. 7A, 7B). The remaining PDCs in the BM showed partial recombination, while no PDCs 
could be detected in the spleen (Fig. 7A, 7B).  
 
PDC-less mice do not develop spontaneous disease 
PDC-deficient CKO mice did not display any obvious signs of disease. Moreover, mice of 
approximately 10-15 months of age housed in a specific pathogen-free facility constitutively 
lacked PDCs (Fig. 8A) and did not exhibit any evidence of autoimmunity or other disease. The 
overall cellularity of aged CKO mice did not vary compared to control animals (Fig. 8B). The T cell 
compartment, including FoxP3+ regulatory T cells, was also unaffected (Fig. 9A, 9B).  
 
PDC-less mice control infection with Listeria 
To determine if PDC-deficient mice were generally defective in control of intracellular 
pathogens, we tested the response of PDC-less mice to Listeria infection. CKO mice were able to 
respond normally to L. monocytogenes, producing comparable levels of antigen-specific and 
IFNγ+ T cells and normal viral titers (Fig. 10A-D). This result indicated that the immune cells 
involved in the response to Listeria were not functionally impaired by E2-2 targeting in CD11c+ 
cells.  
 
PDC-less mice fail to control MHV infection 
In order to test the role of PDCs in the early, innate protection from an acute cytopathic 
virus, PDC-deficient mice were infected with the coronavirus, MHV A59 and analyzed 2 days 
later. CKO mice were unable to produce a normal IFNα response to infection in comparison to 
control animals (Fig. 11A). MHV infection caused uncontrolled disease in PDC-less mice within 
48 hours, as evidenced by the widespread viremia (Fig. 11B), liver damage (11C), and leukocyte 
infiltration of the liver (11D). In contrast, MHV load was significantly restricted in the liver, spleen, 
and lung of control animals. Minimal liver damage and inflammation, as measured by serum ALT 
levels and histology, was observed in immunocompetent control mice.  
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PDCs control the T cell response to chronic LCMV infection 
To compare differences in the role of PDCs during acute and chronic infections, PDC-
less and control mice were infected with strains of LCMV that cause acute infections that are 
normally cleared by immunocompetent mice or a persistent LCMV strain that has been used to 
model chronic viral infections. PDC-deficient and control mice responded equivalently to infection 
with either of the acute strains, LCMV-Armstrong and LCMV-WE, and effectively controlled 
infection, as exhibited by systemic viral clearance 28 days after infeciton (Fig. 12D). To establish 
persistent infection of PDC-deficient and control mice, animals were infected with a high dose of 
LCMV-Docile, and analyzed 7 or 30 days after infection. After widespread viremia within the first 
week of infection, the virus was cleared from the blood and lymphoid organs, persisting only in 
the kidneys of control mice by day 30. In contrast, PDC-less mice failed to clear the virus from the 
blood or spleen within 30 days, demonstrating that PDCs are required to restrict the virus from 
lymphoid organs during LCMV-Docile infection.   
 After 7 days of infection, the fraction of LCMV-specific MHC class I tetramer-binding 
CD8+ T cells was significantly reduced and remained so 30 days after infection in PDC-deficient 
mice, as measured after restimulation with LCMV-specific peptides (Fig. 12A). The frequency of 
LCMV-specific IFNγ-positive CD8+ T cells was also significantly reduced 7 and 30 days post-
infection (Fig. 12B). The fraction of IFNγ-positive CD4+ T cells was reduced 7 days post-infection 
and remained low 30 days after infection (Fig. 12C). These data show that the absence of PDCs 
led to a defect in T cell responses.  
 To determine how PDCs affect this outcome, LCMV gp61 peptide-specific CD4+ T cells 
were isolated from SMARTA1 mice and transferred into LCMV-Docile-infected control and CKO 
mice. Seven days later, the fraction of donor T cells was over 5-fold reduced in CKO mice (Fig. 
13A), indicating that PDCs were required for efficient CD4+ T cell expansion following transfer. 
Furthermore, the remaining donor T cells had elevated levels of T cell exhaustion markers, PD-1 
and BTLA, and impaired cytokine production suggesting that the lack of PDCs led to increased T 
cell exhaustion (Fig. 13B, 13C). LCMV-specific CD4+ T cells lacking the IFNα receptor (IFNAR) 
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were isolated from SMARTA1 IFNAR-/- donors and transferred with SMARTA1-derived CD4+ T 
cells to infected hosts (Fig. 13D). IFNAR-deficiency completely eliminated donor T cell expansion 
in control and CKO animals (Fig. 13E), indicating that PDC-derived IFNα/β contributed to the 
expansion of LCMV-specific CD4+ T cells.  
To determine if PDC-mediated antigen presentation contributed to the control of LCMV 
Docile, chimeras with MHC class II-deficiency were generated from mice with mutations within 
the pIII and pIV promoters of the MHC class II transactivator, CIITA (CIITA pIII/pIV-/-). Since this 
deficiency would necessarily affect MHC class II expression on B cells, B cell-dependent effects 
were discounted by comparing chimeras generated with CIITA pIII/pIV-/- and B cell-deficient 
(µMT) bone marrow to chimeras with B-cell deficiency alone. The absence of MHC class II on 
PDCs had no effect on the expansion of LCMV-specific CD4+ T cells or IFNAR-deficient LCMV-
specific CD4+ T cells, suggesting that antigen presentation by PDCs did not contribute to LCMV-
specific CD4+ T cell expansion (Fig. 13F). Furthermore, MHC class II deficiency on PDCs did not 
affect IFNγ secretion by LCMV-specific CD4+ T cells in comparison to wild-type PDCs, showing 
that inability to present antigen also had no effect on LCMV-specific CD4+ T cell function (Fig. 
13G).   
The contribution of PDCs to CD8+ T cell expansion was tested through the transfer LCMV 
peptide gp33-specific, H2-Db-restricted CD8+ T cells to infected control and CKO mice. Seven 
days after infection, the fraction of donor CD8+ T cells was mildly reduced in mice that lack PDCs, 
and unlike CD4+ T cells, remaining donor CD8+ T cells displayed no evidence of T cell exhaustion 
(Fig. 14). These data demonstrate that CD8+ T cell expansion was not primarily dependent on 
PDCs. Furthermore, IFNAR-deficient, LCMV-specific CD8+ T cells that were competitively 
transferred into infected hosts were unable to proliferate in either control or CKO recipients (Fig. 
14), demonstrating that the CD8+ T cell expansion in CKOs was primarily dependent on type I 





The development of a PDC-less mouse 
  We took advantage of the selective requirement for E2-2 in PDCs to generate the PDC-less 
mice used in this study. E2-2 is a master regulator of the PDC lineage that is not required for the 
development of any other cell type (20). It is, however, expressed at low levels in B cells. 
Therefore, to ensure the specificity of our deletion model, we used CD11c-Cre deleter mice that 
mediate deletion specifically in dendritic cells. Importantly, E2-2 is not expressed in cDCs. PDCs 
also express intermediate levels of CD11c, which can render them intransigent to CD11c-
mediated depletion methods (88). In addition, CD11c expression occurs at a late stage in PDC 
differentiation. To enhance the deletion efficiency of CD11c-Cre and to introduce the 129 
background, we bred E2-2fl/fl CD11c-Cre+ mice to E2-2 heterozygotes. The B6/129 F1 
background was selected to reduce possible strain biases and maximize potential uses for these 
mice.  
  The targeting method employed effectively eliminated peripheral PDCs without affecting the 
presence of any other cell type. CD11c-Cre-mediated recombination occurred primarily in 
dendritic cells, with little recombination evident in B cells. E2-2 heterozygous mice had normal T-
dependent antibody responses (20), indicating that E2-2 depletion does not affect B cell function. 
Furthermore, normal immune responses to Listeria and LCMV-Armstrong demonstrate that PDC-
less mice are otherwise functionally replete. 
  An unresolved question is the fate of the residual immature PDCs present in the BM. It is 
uncertain if these cells accumulate as “failed” PDCs, if they exit the BM, or if they differentiate into 
another cell type. We have recently shown that continuous expression of E2-2 is necessary to 
maintain the PDC lineage and identified a B220+CD8+ DC population that arises in PDC-less mice 
crossed to a CD11c-Cre-driven YFP reporter (90). However, we were unable to detect this 
population without the use of the YFP transgene. This could be because of the difference in strain 
generated through the YFP cross or because YFP expression is necessary to clearly distinguish 
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this subset. Since we have not identified any function for this minor cell population and 
B220+CD8+ DCs were not present at detectable levels in PDC-less mice, it is unlikely that they 
contributed to the observed phenotypes.  
  Outside of the bone marrow, PDCs were absent from every organ examined, including the 
spleen, LN, thymus, lung, and liver. Preliminary analysis of the small intestine has shown 
absence of PDCs from the lamina propria (Fig. 15). This not only confirms that PDCs require E2-
2 regardless of their resident tissue, but also highlights the bone marrow as a unique site for PDC 
development. The signals that regulate E2-2 expression and immature PDC development in the 
bone marrow remain unknown.  
 
 
Figure 15. PDCs are absent in the intestinal lamina propria of PDC-less 
mice. Percentage of PDCs out of total cells is shown.  
    
  We have developed a novel model of constitutive, specific, and complete deletion of 
peripheral PDCs. Previous studies of PDC function have relied on transient diphtheria toxin-
mediated targeting, non-specific genetic deletion approaches or incomplete antibody-mediated 
depletion methods. Our PDC-less model is unique in its suitability for long-term studies and will 
be vital in uncovering PDC function in chronic diseases, autoimmunity, cancer, and tolerance.  
 
Defining the role of PDCs in viral infection 
  Previous studies using BDCA2-DTR to deplete PDCs suggested that PDCs contribute to 
response to MCMV and VSV (53, 54). However, these studies failed to demonstrate an essential 
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role for PDCs in control of a viral infection. Our results definitively show that PDCs are required 
for the immune response to acute infection with MHV. To investigate the role of PDCs in a 
persistent infection, we chose the LCMV Docile strain as its course of infection most closely 
resembles that of relevant human infections, such as HIV. At high doses, LCMV Docile infection 
is marked by rapid and widespread early replication, followed by clearance from most organs, 
finally resulting in persistence in reservoir tissue. Infection with LCMV Docile led to impaired T cell 
responses, T cell exhaustion, and failed clearance of the virus in PDC-less mice. In comparison, 
high dose infection with LCMV Cl. 13, a strain that induces overwhelming CTL exhaustion even in 
immunocompetent mice, could not be exacerbated by the absence of PDCs. These data 
demonstrate that PDCs are required to activate LCMV-specific T cell responses and prevent T 
cell exhaustion during LCMV Docile infection.  
  To dissect the role of PDCs in directing the differentiation of virus-specific CD4+ and CD8+ 
T cells, LCMV-specific CD4+ T cells from SMARTA mice were transferred into infected animals. 
PDC-less mice were unable to efficiently induce the expansion donor CD4+ T cells. Further 
examination showed that the residual T cells had an exhausted phenotype. In contrast, transfer of 
LCMV-specific CD8+ T cells led to a mild reduction in CD8+ T cell expansion and no evidence of 
exhaustion in PDC-less mice. Taken together, these data suggest that PDCs directly activate 
CD4+ T cells, and thus, through CD4+ T cell help, indirectly affect CD8+ T cells (Fig. 16).  
  To determine whether PDCs exerted this effect through the secretion of IFNα or antigen 
presentation, the effects of IFNAR- and MHC class II-deficiency were compared. IFNAR 
deficiency eliminated LCMV-specific CD4+ T cell expansion, while MHC class II-deficient PDCs 
showed no impairment in their activating effect on LCMV-specific CD4+ T cells. These data 
strongly suggest that PDC-derived IFNα rather than PDC-mediated antigen presentation plays 
the crucial role in activating virus-specific CD4+ T cells, thereby preventing CD4+ T cell 
exhaustion and promoting CD4+ T cell helper functions during chronic LCMV. These results imply 
that boosting the activity of PDCs or supplementing their loss may help to prevent T cell 
exhaustion and associated pathology in persistent viral infections. In fact, the decline in PDCs 
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during chronic HCV leads to impaired CD4+ T cell stimulation in human patient samples (91). 
PDC loss is also correlated with reduced CD4+ T cells, increased viral load, and the 




Figure 16. PDCs are required to control T cell responses to chronic viral 
infection. PDCs promote the CD4+ helper T cell response to persistent LCMV-
DOCILE infection through the secretion of type I interferon and indirectly affect 
CD8+ T cell expansion. In the absence of PDCs, CD4+ T cells exhibit signs of 
early exhaustion and both CD4+ and CD8+ T cells fail to expand, resulting in 




    Recent studies have implicated a role for PDCs in immune responses to non-viral 
pathogens, including Aspergillus and Legionella (94, 95). In fact, it is likely that the full pathogen 
recognition repertoire of PDCs has yet to be revealed. TLR7 and TLR9 are effectively stimulated 
with synthetic agonists, but little is known about the exact nature and range of biological ligands 
that these TLRs detect. Furthermore, other pattern recognition receptors expressed by PDCs 
such as TLR12 and Clec9A may be involved in sensing pathogens. Current investigations into 
how PDCs respond different pathogen-associated ligands will be aided by testing the specificity 
of these responses using the PDC-less model generated in this study. This model will also be 








The role of E2-2 and PDCs in autoimmunity  
  Preliminary investigation into the role of E2-2 in systemic lupus erythematosus (SLE) has 
led to surprising results regarding its role in disease development. Using a TLR7 transgenic 
model of lupus-like inflammation, we found that monoallelic deletion of E2-2 markedly improved 
resistance to disease as measured by diminished myeloid cell expansion, reduced circulating 
activated T cells, and enhanced survival (Fig. 17). These data imply a disease-enhancing role for 
E2-2, which is also supported by studies suggesting that chronic activation of PDCs contributes to 
disease in human lupus patients. Current studies are now focused on determining the role of E2-
2 and PDCs in more relevant models of lupus, including the multigenic Sle123 model. In addition, 
E2-2 was found to directly bind to the IRF5 promoter region (90). IRF5 polymorphisms have been 
associated with increased susceptibility to SLE in humans and IRF5 deficiency leads to reduced 
disease development in lupus-prone FCγRII
-/- Yaa mice (96). We are actively investigating 
whether E2-2 is an upstream regulator of IRF5 and if TCF4 is involved in the SLE susceptibility 
associated with the 18q21 locus. 
 
    
 
 
Figure 17. E2-2-deficiency promotes survival from lupus-like disease. 
Survival of TLR7.tg+ E2-2+/- (het) and TLR7.tg+ E2-2+/+ (ctrl) was compared. 





We have also begun to investigate the role of E2-2 and PDCs in EAE and psoriasis. 
Initial observations of 2D2 transgenic mice failed to show survival differences or signs of 
spontaneous development of EAE or optic neuritis, regardless of E2-2 deficiency. However, 
subclinical disease has yet to be thoroughly examined in these mice. Adoptive transfer and MOG 
induction of EAE will also be investigated using PDC-less mice to understand the role of PDCs in 
EAE. PDC-less mice are also being used in ongoing research into the development of imiquimod-
induced psoriasis. Finally, we plan to use PDC-less mice to study the specific role of PDCs in the 
intestine in the steady-state and in gastrointestinal disease such as colitis and cancer. 
 
The generation of mice that constitutively lack PDCs has helped to confirm the function of 
PDCs in the innate control of an acute viral infection, and has also uncovered a novel role for 
PDCs in the adaptive immune response to a persistent viral infection. The importance of PDC-
derived IFNα/β in preventing T cell exhaustion can help to explain the therapeutic role of type I 
IFN treatment in infections such as HCV and HIV. Therefore, specific support of PDC activity may 
represent a novel therapeutic approach to treat chronic viral infections. Finally, the PDC-less 
model developed in this study is unique in its suitability for long-term analyses and will enable 









Dendritic cell-specific deletion using the CD11c-Cre (Itgax-Cre) hemizygous transgene has been 
previously described (10). CD11c-Cre mice were crossed to animals carrying homozygous 
conditional alleles of E2-2. Resulting E2-2fl/fl CD11c-Cre+ progeny were crossed to mice with 
heterozygous germline E22 deletion on a 129SvEvTac (129) background to generate E2-2fl/-  
CD11c-Cre+ “PDC-less” mice with a defined B6/129F1 background. Cre-negative littermates were 
used as controls since CD11c-Cre does not affect DC numbers or phenotype (10). PDC-less 
mice were generated at Columbia University and shipped to Kantonal Hospital St. Gallen for 
analysis. Previously described reporter mice that express enhanced yellow fluorescent protein 
(EYFP) upon Cre recombination (Gt(ROSA)26Sor-EYFP) (97) were crossed to E2-2 
heterozygotes (Sv129). YFP+ E2-2fl/- offspring were then bred with E2-2fl/fl CD11c-Cre+ mice to 
generate R26-YFP+ E2-2fl/- CD11c-Cre+ animals on a mixed B6/129 background. Bone marrow 
chimeras lacking MHC class II on PDCs (μMTxpIII/IV-/-:WT) and controls (µMT:WT) were 
generated as previously described (69). 
All experimental mice were on the C57BL/6 (B6) background except where indicated 
otherwise. All animal work was performed according to protocols approved by the Columbia 
University Institutional Animal Care and Use Committee.  
 
Cell analysis 
Isolation and analysis of primary cells from lymphoid organs was performed as described (7, 10, 
98). PE-conjugated tetramers for LCMV gp34-41 was purchased from Sanquin (Amsterdam, The 
Netherlands), and LCMV gp33-41 and LCMV np396-404 were previously described (99). 
Conjugated antibodies against indicated markers were purchased from eBiosciences, BD 
Biosciences, or Biolegend. Samples were analyzed by flow cytometry using an LSRII or 
FACSCaliber (BD) and analyzed using FlowJo or CellQuest software (Tree Star, Inc.). 
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IFNα  assays 
To measure IFNα production in vitro, 2 x 105 splenocytes or bone marrow cells were incubated for 
48 hours at 37°C with 1 µM CpG-A oligonucleotides (ODN 2216, Invivogen). For analysis of IFN 
induction in vivo, mice were injected i.v. with 5 µg CpG-A and 30 µl DOTAP (Roche) in 150 µl 
total volume, and serum was collected 6 hours after injection. IFNα present in supernatants or 
sera was measured by ELISA with anti-murine IFN-α antibodies and recombinant standard, 
according to manufacturer’s instructions (PBL Biomedical). 
 
Listeria infection 
Control and CKO mice were infected with 104 cfu of ovalbumin-expressing Listeria 
monocytogenes (100). Ovalbumin peptide-specific CD8+ T cells in the peripheral blood and 
spleen were detected with PE-conjugated H2-Kb-Ova peptide tetramer (Beckman Coulter). The 
fractions of splenic CD4+ and CD8+ T cells producing IFN-γ were measured upon restimulation 
with 100 ng/ml PMA and 1µg/ml ionomycin for 1 hour at 37°C, 8 days after infection. Brefeldin A 
(10 μg/ml) was added and the cells were incubated for another 3 hours at 37°C. Cells were then 
surface-stained, fixed with Cytofix-Cytoperm (BD Biosciences) for 20 minutes, and then stained 
for intracellular cytokines by incubating in permeabilization buffer (2%FCS, 0.5% saponin in PBS) 
containing either APC-labeled anti-IFNγ  (BD Biosciences), according to manufacturer’s 
instructions. 
 
Cells and viruses. 
All viral production and infections were performed by at Kantonal Hospital St. Gallen. Mouse 
hepatitis virus strain A59 (MHV A59) was propagated on 17Cl1 cells. Mice were injected i.p. with 
50 pfu MHV A59, and titers were determined plaque assay using L929 cells. Lymphocytic 
choriomeningitis virus (LCMV) strains were obtained from Dr. Zinkernagel (University of Zurich, 
Switzerland). LCMV Armstrong was propagated on L929 cells and LCMV Docile was propagated 
on MDCK cells. Mice were injected i.v. with 103 pfu LCMV Armstrong or 105 LCMV Docile, and 
titers were determined using a focus forming assay with MC57 cells.  
 33 
 
Histology and ALT measurement 
Livers were fixed in 4% formalin, paraffin-embedded, and stained with hematoxylin and eosin. 
Alanine 2-oxoglutarate-aminotransferae (ALT) was measured from serum with a Hitachi 747 
autoanalyzer.  
 
In vitro stimulation 
To measure peptide-specific cytokine production, 106 splenocytes were restimulated with gp33-
41, gp34-41, np396-404, or gp61-80 peptides in medium containing Brefeldin A (5 μg/ml) for 5 
hours at 37°C. Cells were stimulated with PMA (50 ng/ml, Sigma) and ionomycin (500ng/ml, 
Sigma) as a positive control. Cells were stained for surface markers, fixed in Cytofix-Cytoperm 
(BD Biosciences) for 20 minutes, and then stained with anti-IFNγ mAb in permeabilization buffer 
(2%FCS, 0.5% Saponin in PBS).  
 
Adoptive transfer of TCR transgenic cells. 
Splenocytes from SMARTA1+ Ly5.1+, SMARTA1+ IFNAR-/-, IFNAR-/- Thy1.1+, P14 Thy1.1+, and 
P14 IFNAR-/- Ly5.1+ were injected i.v. into recipients (2.5 x 103 cells per animal). For competitive 
transfers, 5 x 103 donors cells of each population was injected.  
 
Statistical analysis 
All statistical analyses were performed with Prism 4.0 (Graphpad Software Inc.). Data were 
analyzed with the unpaired Student's t-test assuming that the values followed a Gaussian 













FIGURES I  
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Figure 4.  Constitutive depletion of E2-2 results in specific absence of peripheral PDCs 
 
Conditional knockout animals (CKO) with dendritic cell-specific deletion of one allele of E2-2 and 
one germline-deleted allele (E2-2fl/- CD11c-Cre+) were analyzed in parallel with Cre-negative 
littermate controls (Ctrl) with one floxed and one wild-type copy of E2-2 (E2-2fl/wt CD11c-Cre-). 
Statistically significant differences are indicated: ***, p < 0.001; **, p < 0.01; *, p < 0.05. 
(A) Representative staining profiles of bone marrow (BM) and splenic PDC, with the percentages 
of Bst2+ CD11cint PDCs highlighted (mean ± S.D. of 3-4 animals for the BM and 9 animals for the 
spleen).  
(B) Representative staining profiles of splenic cDCs, with the fraction of CD11chi MHC class II+ 
cDCs highlighted in the left panels and the percentages of CD11b+ or CD8+ DC subsets within the 
cDC gate shown in the right panels (mean ± S.D. of 7 mice).  
























Figure 5.  Constitutive targeting of E2-2 depletes PDCs in diverse organs  
 
Representative staining profiles PDCs in the lymph nodes (LN), thymus, lung, and liver from CKO 
(E2-2fl/- CD11c-Cre+) and littermate control (Ctrl) animals (E2-2fl/wt CD11c-Cre-). The fraction of 
Bst2+ CD11cint PDCs is highlighted (mean ± S.D. of 9 animals for the LN and 5-6 animals for 



















0.3 ±0.1 0.04 ±0.03*** 
0.5 ±0.2 0.05 ±0.02** 
0.3 ±0.2 0.04 ±0.02* 




Figure 6.  PDC ablation impairs interferon-α  response 
 
(A) IFN-α production in supernatants from bone marrow (BM) or splenocytes of (CKO) (E2-2fl/- 
CD11c-Cre+) or control (E2-2fl/wt CD11c-Cre-) animals after culture for 48 hours with CpG-A DNA 
(mean ± S.D. of 3-5 animals) 
(B) IFN-α production in the serum of CKO or control animals, 6 hours after challenge with CpG-A 
DNA (mean ± S.D. of 3 animals). 























Figure 7.  Recombination specificity of conditional E2-2 targeting.  
 
Expression of a Cre-inducible YFP reporter in CKO animals (Gt(ROSA)26Sor-EYFP+ E2-2fl/- 
CD11c-Cre+). Histograms of EYFP fluorescence in bone marrow (A) or spleen (B): B220+ Bst2- B 
cells (red), TCRβ+ T cells (orange), DX5+ NK cells (light green), Ter119+ erythroid cells (dark 
green), Gr1+ SSChi cells (blue), CD11bhi Gr1lo-neg CD11clo-neg MHCII- monocytes or macrophages 
(pink), CD11cint Bst2+ PDCs (grey), and CD11chi MHCII+ CD11b+ (purple) or CD11chi MHCII+ 























































Figure 8.  Long-term PDC absence does not cause spontaneous disease 
 
The total cellularity of different organs in 10-15 month-old CKO animals analyzed in parallel with 
control mice. Statistically significant differences are indicated: ***, p < 0.001; **, p < 0.01; *, p < 
0.05. 
(A) Fraction of CD11cint Bst2+ PDCs in spleen (SP), lymph nodes (LN), and lungs.  
(B) Fractions of B220+ cells (including PDCs), TCRβ+ T cells, DX5+ NK cells, Gr1+ SSChi 















































































































Figure 9.  Absence of PDCs does not alter the T cell compartment.  
 
T cell subsets in 10-15 month-old CKO animals analyzed in parallel with control mice.  
(A) Percentage of CD4+ or CD8+ T cells in spleen or lymph nodes. 































































Figure 10.  PDC-deficient mice mount an effective response to Listeria infection 
 
Control and CKO mice were infected with ovalbumin-expressing Listeria monocytogenes (LM-
OVA)  
(A-B) The fractions of ovalbumin peptide-specific CD8+ T cells among total CD8+ T cells in the 
peripheral blood on day 6 (A) or spleen on day 8 (B) post-infection.  
(C-D) The fractions of IFNγ+ CD4+ (C) or CD8+ (D) T cells among their respective T cell subset 






























































































































































Figure 11.  PDC-less mice fail to clear MHV infection 
 
Experiment performed by Luisa Cervantes-Barragan  
Control and CKO mice were injected i.p. with 50 pfu MHV A59 and analyzed 48 hours after 
infection (n=5 animals per genotype). Statistically significant differences are indicated: ***, p < 
0.001; **, p < 0.01; *, p < 0.05. 
(A) IFN-α levels in serum as measured by ELISA (mean± S.D.). 
(B) MHV titers in liver, spleen and lung (mean± S.D.). 
(C) Serum alanine aminotransferase (ALT) levels (mean± S.D.). 
(D) Representative hematoxylin/eosin stains of liver sections. Arrows indicate inflammatory foci 





















Figure 12.  Impaired T cell response to chronic LCMV infection in absence of PDCs 
 
Experiment performed by Luisa Cervantes-Barragan and Sonja Firner (9D) 
Control and CKO mice were injected i.v. with 105 pfu LCMV Docile and analyzed 7 and 30 days 
after infection. Splenocytes were stained with LCMV peptide-MHC class I tetramers (tet) or 
stimulated with LCMV peptides and stained for IFNγ. 
 (A) Percentage of tetramer-positive CD8+ T cells that are specific for indicated peptides (mean± 
S.D. of 8-11 mice, pooled from 3 independent experiments). 
(B) Percentage of IFNγ-positive CD8+ T cells that are specific for indicated peptides (mean± S.D. 
of 8-11 mice, pooled from 3 independent experiments). 
(C) Frequency of gp61-responsive, IFNγ-positive CD4+ T cells (mean± S.D. of 7 mice, pooled 
from 2 independent experiments). 




















Figure 13.  IFN produced by PDCs is required for CD4+ T cell response to chronic LCMV 
 
Experiment performed by Luisa Cervantes-Barragan and Sonja Firner 
Control or CKO mice were infected with 105 pfu LCMV Docile one day prior to receiving 5 x 103 
LCMV peptide gp61-specific SMARTA1 (SM1) TCR transgenic CD4+ T cells. Mice were analyzed 
8 days after infection. Data represent 8 animals per group.  
(A) Fraction of transferred Thy1.1+ cells within total CD4+ T cells in the spleen  
(B) Surface expression levels of PD-1 and BTLA on transferred CD4+ T cells. 
(C) Percentage of IFNγ-positive, TNFα-positive, or IL-2-positive transferred CD4+ T cells (mean± 
S.D.). 
 
A 1:1 mixture of wild-type SMARTA1 and IFNAR-deficient SMARTA1 TCR transgenic CD4+ T 
cells was transferred into LCMV Docile infected control or CKO mice, as above. Mice were 
analyzed 8 days after infection. Data represent 8 animals per group. 
(D) Experimental set-up and representative FACS profile of transferred T cell mixture. 
(E) Fraction of transferred Thy1.1+ SMARTA1 cells or Ly5.1+ IFNAR-/- SMARTA1 cells within total 
CD4+ T compartment of recipient spleens (mean± S.D.). 
 
Chimeras were generated by transferring bone marrow from µMT or µMTxpIII/pIV CIITA knockout 
bone marrow into lethally irradiated wild-type recipients. Following reconstitution, a 1:1 mixture of 
wild-type SMARTA1 and IFNAR-deficient SMARTA1 TCR transgenic CD4+ T cells was 
transferred into LCMV Docile infected chimeras, as above. Mice were analyzed 8 days after 
infection. Data represent 4 animals per group. 
(F) Percentage of transferred Thy1.1+ SMARTA1 cells or Ly5.1+ IFNAR-/- SMARTA1 cells within 
total CD4+ T compartment of recipient spleens (mean± S.D.). 






Figure 14.  Graphical summary of experimental set-up and outcomes.  
 
(A) LCMV-specific CD4+ T cells proliferated when transferred into LCMV-infected mice.  
(B) In the absence of PDCs, LCMV-specific CD4+ T cells failed to expand and displayed signs of 
functional exhaustion.  
(C) IFNAR-deficient LCMV-specific CD4+ T cells failed to expand.  
(D) MHC class II-deficiency on PDCs had no effect on the proliferation of LCMV-specific CD4+ T 
cells 
(E) LCMV-specific CD8+ T cells underwent expansion when transferred into LCMV-infected mice.  
(F) In the absence of PDCs, LCMV-specific CD4+ T cells expanded slightly less efficiently.  






















































The genetic identity of PDCs  
The identification of E2-2 as a specific and master regulator of PDC development has 
enabled better understanding of the PDC lineage. Prior to the discovery of the role of E2-2 in 
PDCs, SpiB and IRF8 were also identified as important in PDC development (17, 19). However, 
the role of SpiB has not been demonstrated in vivo and neither of these transcription factors is 
uniquely expressed in PDCs. As shown in Chapter 1, E2-2 is required for the development of all 
peripheral PDCs, but not other cell types. Microarray and ChIP analysis of E2-2-depleted cells 
and CAL1, a human PDC cell line, have identified targets of E2-2 and revealed the unique 
genetic signature of PDCs (Fig. 18). This signature set includes PDC-related genes that are 
upregulated and cDC-specific genes, including Itgax and Id2 that are downregulated by E2-2 in 
PDCs. 
  
       Ghosh, et al. Immunity 2010 (90) 
Figure 18. Direct binding of E2-2 to transcriptional targets. The binding of 
E2-2 to 5’ regions of (A) PDC-specific (B) and cDC-specific genes in the human 




PDCs and CD8+ DCs 
PDCs and CD8+ DC share some similarities, including dependence on IRF8 (17). PDCs 
have also been reported to engage in cross-presentation (101, 102). However, unlike CD8+ DC, 
PDCs develop independently of Batf3 (14). Furthermore, CD8+ DC development requires ID2 
(16), and IRF4 deletion or expression of hypomorphic Ikaros (IkarosL/L) depletes PDCs, but not 
CD8+ DCs. Recently, a CCR9-negative PDC precursor that retains the ability to convert into a 
cDC-like cell in vitro has been identified (103). This conversion coincides with the downregulation 
of E2-2 and upregulation of the CD8+ DC regulators including Id2 and Batf3, which suggests that 




The fate of activated PDCs is an area of continuing investigation. PDCs have long been 
thought to differentiate into cDCs after activation and were in fact originally described as 
precursors of cDCs that could preferentially stimulate Th2 differentiation (35, 104). More recently, 
the conversion of bone marrow PDCs, but not peripheral PDCs, into myeloid DCs after infection 
with LCMV was reported (105). However, the conversion of mature peripheral PDC into functional 
cDCs in vivo has not been conclusively demonstrated.  
 
Here we present evidence that E2-2 is required to maintain the lineage identity of PDCs 
and that deletion of E2-2 in mature PDCs causes their conversion into CD8+ DC-like cells. In 
addition, we identify a novel steady-state population of CD8+ DCs that shares a common genetic 




Continuous E2-2 expression maintains PDC lineage identity.  
The targeting approach outlined in Chapter 1 was used to generate E2-2fl/- CD11c-Cre+ 
(CKO) mice and Cre-negative littermate controls that harbor the Cre-inducible YFP reporter, 
Gt(ROSA)26Sor-EYFP (R26Sor-YFP). This reporter contains an EYFP gene following a LoxP-
flanked stop codon under the ubiquitous promoter, Rosa26. PDCs were diminished in CKO mice, 
as expected (Fig. 19A,B). This reduction was concomitant with the appearance of a CD11c+ 
B220lo population in Cre-expressing YFP+ cells (Fig. 19A,B). The B220lo population did not 
express PDC markers like Bst2 or Ly6C, and expressed elevated levels of CD8 and MHC class II 
in comparison to PDCs from control animals (Fig. 19C). Additional study has shown that this 
B220lo CD8+ DC-like population results from the differentiation of PDCs into cDC-like cells upon 
deletion of E2-2 (90). B220lo CD8+ DC-like cells induce expression of conventional DC signature 
genes, acquire characteristic DC-like morphology, and have increased T cell priming capacity in 
comparison to mature PDCs (90). Therefore, continuous expression of E2-2 is necessary to 
prevent PDCs from differentiating into a “default” cDC pathway (Fig. 25).  
 
Alternative CX3CR1+ CD8+ DCs are a steady-state population related to PDCs 
To examine the heterogeneity of steady-state CD8+ DC populations, splenic DCs from 
Cx3cr1-GFP+ mice were examined for GFP expression. Cx3cr1-GFP+ mice (106) had been 
previously used to study heterogeneity in other cell types including monocytes (107) and 
intestinal lamina propria DCs (108). Two distinct populations of CD8+ DCs were clearly present in 
spleens from these mice, CD8+ GFPlo and CD8+ GFPhi DCs (Fig. 20A). These two cell populations 
could also be detected without the use of the Cx3cr1-GFP transgene; GFPlo CD8+ DCs were 
CD86hi SSChi, and GFPhi CD8+ DCs were CD86lo SSClo CD8+ DCs (Fig. 20B).  
Sorted splenic GFPlo and GFPhi CD8+ DC subsets from Cx3cr1-GFP+ mice were analyzed 
by microarray. GFPlo CD8+ DCs expressed more genes specific to CD8+ DC in comparison to 
GFPhi CD8+ DCs, while GFPhi CD8+ DCs expressed more of the signature genes of PDCs (Fig. 
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21A). However, GFPhi CD8+ DCs do not express PDC-related genes, such as E2-2, SpiB, and 
IRF7, to the level of PDCs, as measured by Q-PCR (Fig. 21B). Therefore, GFPhi CD8+ DCs are 
more related to PDCs than conventional CD8+ DCs by genetic profile, but lack the high level 
expression of hallmark PDC-related genes found in mature PDCs. Further research into the 
differences between splenic GFPlo and GFPhi CD8+ DC revealed that GFPhi CD8+ DCs lack 
several defining features of conventional CD8+ DCs; they develop independently of Batf3, do not 
secrete IL-12 in response to microbial challenge, and are unable to cross-present antigen (15).  
 
Alternative CX3CR1+ CD8+ DCs are dependent on early expression of E2-2. 
To determine if GFPhi CD8+ DCs develop in the absence of E2-2, fetal liver chimeras 
were analyzed. As expected, donor-derived PDCs were completely absent in recipients of E2-2-/- 
fetal liver cells, but developed normally in recipients of wild-type donor cells (Fig. 22A,B). Donor-
derived CD86lo SSClo CD8+ DCs, which correspond to the GFPhi CD8+ DC population, also failed 
to develop in the recipients of knockout donor cells despite normal levels of reconstitution from 
wild-type donors (Fig. 22A,B). E2-2-/- Cx3cr1-GFP+ fetal liver chimeras were also generated and 
analyzed for the presence of GFPhi CD8+ DCs. In agreement with the absence of CD86lo SSClo 
CD8+ DCs in E2-2-/- chimeras, GFPhi CD8+ DCs failed to form in E2-2-/- Cx3cr1-GFP+ recipients, 
further confirming that the CD86lo SSClo CD8+ DCs and GFPhi CD8+ DCs represent the same 
population. In addition, these data demonstrate that E2-2 is required for the development of 
GFPhi CD8+ DCs (Fig. 22C).  
 In order to determine if E2-2 is required for the maintenance of CD86lo SSClo CD8+ DCs, 
E2-2fl/fl CreER+ (CKO) or E2-2fl/fl Cre-negative (Ctrl) mice were treated with tamoxifen to induce 
deletion of E2-2 in mature E2-2-expressing cells. Bone marrow from tamoxifen-treated mice was 
then transferred to irradiated recipients to minimize the toxic effects of tamoxifen treatment on 
non-hematopoietic cells. The fraction of donor-derived PDCs in reconstituted mice was 
significantly, but not completely reduced (Fig. 23A). The high level of residual PDCs most likely 
reflects incomplete deletion of E2-2 due to the minimal tamoxifen treatment. Despite this low level 
of PDC depletion, E2-2 deletion in mature PDCs led to a significant increase in the fraction of 
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B220lo CD8+ DCs detected in CKO bone marrow recipients. The fraction of CD86lo SSClo CD8+ 
DCs was not affected in CKO recipients, demonstrating that they are distinct from the B220lo 
CD8+ DCs that arise following E2-2 deletion and do not require continuous E2-2 expression for 
their maintenance.  
 Finally, E2-2fl/- CD11c-Cre+ R26Sor-YFP+ (CKO) mice were examined for the presence of 
CD86lo SSClo CD8+ DCs. In these mice, complete deletion of E2-2 occurs at a late stage during 
PDC development as evident from the heterogeneous expression of YFP in the residual PDCs of 
the bone marrow in these mice (Fig. 7). The fraction of CD86lo SSClo CD8+ DCs was not affected 
by either the underlying E2-2 heterozygosity or late CD11c-Cre mediated deletion of E2-2 in E2-
2fl/- CD11c-Cre+ R26Sor-YFP+ mice in comparison to control animals (Fig. 23B). This is in contrast 
to the increased proportion of B220lo CD8+ DCs observed in CKOs. Taken together, these data 




Identification of alternative CD8+ DCs 
Previous work has shown that PDCs develop from committed PDC progenitors through a 
pathway that is dependent on the transcription factor E2-2. We now identify two novel populations 
of CD8+ DC-like cells: B220lo CD8+ DCs that arise from the deletion of E2-2 in mature PDCs and 
steady-state CX3CR1+ CD86lo SSClo CD8+ DCs that differentiate from an E2-2-dependent 
precursor in the steady-state. These studies demonstrate that E2-2 must be continuously 
expressed to maintain the PDC lineage and prevent divergence into a default cDC-like cell fate 
(Fig. 25). 
Although the origin of CX3CR1+ CD86lo SSClo CD8+ DCs remains unclear, it seems 
unlikely that they arise from mature PDCs. Unlike B220lo CD8+ DCs, GFPhi CD8+ DCs did not 
accumulate after tamoxifen-induced deletion of E2-2 from peripheral PDCs (Fig. 23A). 
Furthermore, CD86lo SSClo CD8+ DCs were not affected by the constitutive loss of peripheral 
PDCs (Fig. 23B). However, these data do not exclude the possibility that CD86lo SSClo CD8+ DCs 
arose from “failed” PDCs in the periphery, although this conversion would require dramatic 
upregulation of Cx3cr1-GFP. Further study is necessary to validate this hypothesis.   
 
Functional role of alternative CD8+ DCs 
Neither of the alternative CD8+ DC populations represents bona fide conventional CD8+ 
DCs as both appear unable to cross-present antigen, a defining feature of CD8+ DCs. In fact, a 
clear functional role for both cell types has yet to be identified. Although B220lo CD8+ DCs have 
not been detected in wild-type mice, E2-2 is rapidly downregulated upon PDC activation, 
indicating that the B220lo CD8+ DC fate may result from activation-induced PDC conversion. 
Alternatively, B220lo CD8+ DCs may be functionally inert and their differentiation may simply serve 
as a means to down-regulate PDC activity. Similarly, it remains unclear whether CX3CR1+ CD86lo 
SSClo CD8+ DCs serve a particular function or if they result as a nonfunctional by-product of the 
PDC development pathway.  
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Despite the lack of evidence that alternative CD8+ DCs are functionally related to 
conventional CD8+ DCs, it is tempting to speculate about the potentially intersecting roles of 
PDCs and CD8+ DCs as both of these cell types are suited to respond to intracellular pathogens. 
For example, the immune response to viruses could be enhanced by the direct conversion of 
IFNα/β-secreting PDCs into CTL-priming CD8+ DCs. Evidence for conversion into B220lo CD8+ 
after PDC activation in the context of viral infection is an active area of investigation. 
 
E2-2 overexpression  
A prediction based on the model presented in Figure 25 is that enforcing E2-2 expression 
would suppress the cDC cell fate. The effect of overexpression of E2-2 is currently being 
investigated. Preliminary results suggest that overexpression of E2-2 in DCs leads to repression 
of cDC-specific genes, although further work is needed to verify results.  
    
 
  Ghosh, et al., Immunity 2010 (90) 
  
Figure 25. Deletion of E2-2 triggers PDC conversion to cDC-like cells. 
E2-2 directly regulates the expression of transcription factors that reinforce the 
PDC lineage in opposition to a cDC-like state.  
 
 The identification of E2-2-dependent alternative DC fates reinforces the notion that 
continuous E2-2 expression is required to maintain the PDC lineage. The discovery of these 
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subsets also suggests that PDCs retain the potential to differentiate into a cDC-like fate through 
down-regulation of E2-2. However, the biological significance of alternative CD8+ DCs remains to 





The generation of dendritic cell-specific E2-2 deleter mice and R26-YFP+ E2-2fl/- CD11c-Cre+ 
reporter mice are described in Chapter 1. Cx3cr1-GFP+/+ (C57BL/6) mice, which are 
CD45.1+/Ly5.1+, were maintained through an intercross before breeding to E2-2 heterozygotes 
(Sv129) to generate Cx3cr1-GFP+ E2-2+/-  (CD45.1+CD45.2+) mice on a B6129F1 background. 
Fetal liver chimeras were generated by intercrossing Cx3cr1-GFP+ E2-2+/-  mice with E2-2+/-  mice 
and transferring 1-2 x 106 cells from E13.5-17.5 fetal livers into lethally irradiated (1500 rad) 
B6.SJL recipient mice. Donor-derived cells were distinguished by the presence of CD45.2/Ly5.2.  
 Inducible E2-2 deleter mice were generated by crossing E2-2fl/fl mice to B6 mice that 
express a tamoxifen-inducible Cre recombinase (Gt(ROSA)26Sor-CreER)(20). To induce deletion 
in E2-2fl/fl Cre-ER+ mice, tamoxifen (Sigma) was administered orally for 2 consecutive days (5 mg 
in 0.1 ml sunflower oil per day). Bone marrow was isolated from these mice six days after the last 
treatment and transferred to lethally irradiated recipients (1200 rad) by retro-orbital i.v. injection. 
All animal work was performed according to protocols approved by the Columbia University 
Institutional Animal Care and Use Committee.  
 
Cell analysis 
Isolation and analysis of primary cells from lymphoid organs was performed as described (10). 
Samples were acquired using an LSRII (BD) and analyzed using FlowJo or CellQuest software 
(Tree Star, Inc.). 
 
Gene expression analysis 
Splenocytes from Cx3cr1-GFP+ mice were depleted of lymphoid and erythroid cells by negative 
selection on MACS columns (Miltenyi) and sorted directly into Trizol LS reagent (Invitrogen). Total 
RNA was extracted and reverse-transcribed. Gene expression levels were determined via SYBR 
Green-based real-time PCR using an MX3000P analyzer (Stratagene), normalized to β-actin, and 
 69 
shown relative to indicated reference samples using the ΔΔCT method, as previously described 
(10). All primers were validated for linear amplification. Microarray analysis of sorted splenic DC 
subsets was performed as described by Bar-on, et al (15). Signature genes of normal CD8+ DC 
and PDC populations were selected based on Robbins, et al. (109), and the average probe 
intensity of these genes in each sample was compared pairwise.  
 
Statistical analysis 
All statistical analyses were performed with Prism 4.0 (Graphpad Software Inc.). Data were 
analyzed with the unpaired Student's t-test assuming that the values followed a Gaussian 
















Figure 19.  Continuous E2-2 expression is required for PDC maintenance. 
 
Conditional knockout animals (CKO) with dendritic cell-specific deletion of one allele of E2-2 and 
one germline-deleted allele and a Cre-inducible YFP reporter (E2-2fl/- CD11c-Cre+ R26Sor-YFP+) 
were analyzed in parallel with Cre-negative littermate controls (Ctrl) with one floxed and one wild-
type copy of E2-2 (E2-2fl/wt CD11c-Cre- R26Sor-EYFP+).  
A) Shown are representative staining profiles of EYFP+ cells with CD11chi B220- cDCs (blue), 
CD11chi B220lo cDC-like cells (red), and CD11clo B220+ PDCs (green). 
B) Fractions of CD11chi B220- cDCs, CD11chi B220lo cDC-like cells, and CD11clo B220+ PDCs 
among total splenocytes in control and CKO animals (mean ± SD of three animals per genotype). 
Statistically significant differences are indicated. N.s., not significant. 
C) Cell surface expression profile of indicated proteins on PDCs from control mice, and cDC and 






Figure 20.  Identification of a novel CD8+ DC subset  
 
CD8+ DC populations from Cx3cr1-GFP+ mice were examined for GFP expression.  
A) Representative staining profile (left) of CD11chi MHC class II+ cells with CD8+ GFPlo (blue) and 
CD8+ GFPhi (red) fractions of cDCs highlighted, and histogram (right) of GFP expression within 
CD11chi MHC class II+ CD8+ cells with fraction of GFP+ cells within CD8+ DCs highlighted.  
B) Representative staining profile (left) of CD11chi MHC class II+ CD8+ cells with fractions of 
subsets highlighted, and expression of GFP within corresponding CD86lo SSClo (red) and CD86hi 
SSChi (blue) subsets (right).  
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Figure 21  Alternative CD8+ DCs share the expression signature of PDCs 
 
Microarray prepared by Steffen Jung lab; analysis performed by Boris Reizis. 
A) Microarray analysis of sorted GFPlo and GFPhi CD8+ cDC subsets from splenocytes of Cx3cr1-
GFP+ mice was performed and the average probe intensity of signature CD8+ DC and PDC genes 
was compared. Signature genes of normal CD8+ DC and PDC populations were selected based 
on Robbins, et al. (109).  
B) Relative expression of indicated genes in sorted GFP+CD8+ cDCs, CD11b+ cDCs, and PDCs 
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Figure 22.  Alternative CD8+ DCs are dependent on E2-2. 
 
Absence of PDCs and CX3CR1+ CD8+ DCs in chimeras with deletion of the transcription factor 
E2-2 (KO, E2-2-/-) in comparison to control chimeras (Ctrl). Chimeras were made by transplanting 
E2-2-/- or E2-2+/+ fetal liver cells (CD45.2+ CD45.1+) into lethally irradiated CD45.1+ recipients 
(A,B). E2-2-/- GFP+ chimeras were generated by transferring livers cells from E2-2-/- Cx3cr1-GFP+ 
fetuses (C).  
A) Representative staining profiles of donor-derived (CD45.2+) splenocytes from KO or control 
chimeric mice. Fractions of CD11chi Bst2- cDCs and CD11cint Bst2+ PDCs within total donor cells 
of reconstituted mice are indicated (left). Shown also are representative staining profiles of donor-
derived, CD11chi CD8+ control and KO splenocytes with fraction of the CD86lo SSClo subset within 
CD8+ cDCs highlighted (right). Data are representative of three animals. 
B) Fraction of total PDCs (left) or CD86lo SSClo CD8+ DC (right) among total splenocytes in E2-2 
control or KO chimeric mice. (Mean ± S.D. of 3 recipients). 
C) Histogram of GFP expression within donor-derived (CD45.2+) CD8+ cDCs in E2-2-/- Cx3cr1-
GFP+ (KO, red) splenocytes compared to splenic CD8+ cDCs from non-chimeric Cx3cr1-GFP+/+ 

































































Figure 23.  Steady-state alternative CD8+ DC fractions are not affected by the absence of 
peripheral PDC. 
 
A) Fraction of donor-derived CD86lo SSClo CD8+ cDCs, PDCs, and CD8+ B220lo cDC-like cells 
among total splenocytes in recipient mice reconstituted with bone marrow from tamoxifen-treated 
E2-2fl/fl CreER+ (CKO) or E2-2fl/fl Cre-negative (Ctrl) mice (mean ± S.D. of 3 recipients). Mice were 
analyzed 7-8 weeks following transfer. *, p < 0.05.  
B) Staining profiles of YFP+ CD8+ cDCs with the percentage of CD86lo SSClo cells highlighted 
(left) and of YFP+ splenocytes with the fraction of CD11cint Bst2+ PDCs shown from E2-2fl/- 
CD11c-Cre+ R26Sor-YFP+ (CKO) or E2-2fl/wt CD11c-Cre- R26Sor-EYFP+ (Ctrl) mice. 
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Figure 24.  PDC development and relationship with alternative CD8+ DCs. 
 
PDC progenitors and mature PDCs retain the potential to default into an alternative CD8+ DC cell 
fate through down-regulation of E2-2 or upregulation of its inhibitor, Id2. In the complete absence 
of E2-2, neither PDCs nor alternative CD8+ DCs arise. Deletion of E2-2 during a later stage in 
development, as occurs through CD11c-Cre-mediated deletion, eliminates peripheral PDCs, but 
does not affect the CX3CR1+ CD86lo SSClo alternative CD8+ DC population. However, targeting of 
E2-2 in mature PDCs through inducible systems, such as CreER-mediated deletion, or 
downregulation of E2-2 after virus-triggered PDC activation diverts PDCs into a similar alternative 






















Mononuclear phagocytes encompass a wide range of immune cells with phagocytic 
capacity—from the primitive macrophages that appear in the yolk sac during embryonic 
development to the finely tuned antigen-presenting dendritic cells that form the foundation for 
adaptive immunity. Although strict classifications may be inadequate to describe the full spectrum 
of mononuclear phagocytes that have been discovered, three main groups, monocytes, 
macrophages and DCs, broadly categorize these cells based on shared developmental, 
phenotypic, and functional characteristics. With the exception of those that arise from embryonic 
precursors, mononuclear phagocytes are believed to develop in the bone marrow from a common 
myeloid precursor (MDP). Monocyte and macrophage development is dependent on signaling 
through M-CSF receptor (Csf1R) (110). The DC lineage diverges from MDPs through a common 
DC/PDC precursor (CDP). CDPs give rise to DC-committed precursors, termed preDCs, in the 




Monocytes are circulating blood cells that produce inflammatory cytokines and 
differentiate into macrophages or DCs upon activation, but also mediate homeostatic processes 
in the steady-state. Monocytes do not express high levels of CD11c or MHC class II (111), and 
are not major antigen-presenting cells. Two distinct populations of monocytes have been 
identified in the mouse (107). Ly6Chi “inflammatory” monocytes are recruited to inflamed tissues 
and differentiate into Tip-DCs or macrophages (112), but can also differentiate into DCs or 
macrophages in the absence of inflammation (113). Ly6C- monocytes exhibit an unusual 
migration pattern in the steady-state. Rather than circulate fluidly in the bloodstream, Ly6C- 
monocytes crawl along the endothelium, possibly patrolling the surface for damaged or infected 
cells (114). Therefore, monocytes serve as both effector cells and precursors of other 




Macrophages are phagocytic cells that are proficient at antigen uptake and production of 
pro-inflammatory cytokines during infections. They are also important in the homeostatic 
clearance of apoptotic cells and production of growth factors. Unlike circulating monocytes, 
macrophages are adapted to residence in tissues. The variety of macrophages reflects the 
diversity of environments in which they are found, although the precise function and origin of 
many of these subsets remain unclear. For example, two different types of macrophages reside in 
the marginal zone (MZ) of the spleen: MZ and metallophilic MZ macrophages. Studies have 
demonstrated differences in their precise localization within the MZ and their preference for and 




Dendritic cells were first identified as a novel cell population distinct from macrophages 
based on their “stellate” morphology and unique functional properties, including the ability to 
stimulate naïve T cells (1, 2). Although DCs can be found throughout the body, the spleen has 
become a standard organ for study due to their relative abundance and ease of isolation from this 
organ. During infection, the activity of classical DCs is augmented with monocyte-derived 
inflammatory DCs, including Tip-DCs. However, splenic steady-state DCs are not derived from 
monocytes (116), but develop from preDCs in the spleen (7). 
 Two classical DC subsets have been well described in the spleen. CD11b+, or CD8-, DCs 
make up the majority of DCs in the spleen and are found primarily in the red pulp and MZ (23). 
The development of CD11b+ DCs has been shown to depend on several factors, including RBP-J 
(10), IRF4 (8), IRF2 (9), RelB (11), and signaling through the lymphotoxinβ receptor (12, 13). 
CD8+ DCs constitute the minority of classical DCs and localize to the T cell zone, but can also be 
found in the red pulp and MZ (23, 117). They are specialized in cross-presentation, and are 
dependent on the transcription factors Batf3 (14), Id2 (16), and IRF8 (17). A recently identified 
 88 
Batf3-independent subset of CD8+ DCs that is related to PDCs is described in Chapter 2 (15). 
This population was first identified in Cx3cr1-GFP reporter mice, which have previously been 
used to delineate DC subsets in the intestine (24, 106).   
 
Antigen sampling of the intestines 
There are two main antigen-sampling cell types that reside in the gut: M cells and lamina 
propria DCs (Fig. 26). M cells are specialized cells that sit in the epithelial layer lining Peyer’s 
patches and isolated lymphoid follicles, and take up antigen from the intestinal lumen. Microbes 
and antigens that penetrate the epithelium through M cells are met by a host of organized 
immune cells in Peyer’s patches and isolated lymphoid follicles. Both of these tissues drain to the 
mesenteric lymph node (MLN). The lamina propria (LP) is a layer of tissue beneath the epithelial 
cells of the villi that contains several different types of immune cells, including lymphocytes, 
macrophages, mast cells, and dendritic cells. DCs of the LP can partially penetrate the epithelial 
layer to access antigens from the lumen of the gut. LP DCs also migrate to the MLN where they 
present captured antigen (Fig. 26).  
 
Intestinal DCs 
Three different types of DCs have been identified in the lamina propria (LP): 
CD11b+CD103+, CD103+CD11b-, and CD11b+CD103- DCs. Both CD103+CD11b- and 
CD11b+CD103+ DCs arise from preDCs (24). In contrast, CD11b+CD103- DCs originate from 
monocytes. CD11b+CD103- DCs, which are CX3CR1-positive, extend dendritic processes 
through the epithelial cell layer into the intestinal lumen (108). This has led to the speculation that 
they may be important in the sampling gut antigens, including pathogenic organisms, food, and 
commensal microbes. However, CD11b+CD103- DCs do not appear to migrate to the MLN in the 
steady-state (24). Instead, double-positive CD11b+CD103+ DCs migrate to the MLN in the steady-
state and also efficiently transport Salmonella to the MLN after oral infection (24), suggesting that 
CD11b+CD103+ DCs are the main migratory and antigen presenting LP DC. Thus, the pathogen 
sensing and antigen presenting functions of DCs appear to be divided between two distinct 
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subsets in the intestine. CD103+CD11b- DCs do not selectively express CD8, but have been 
identified as a CD8+-like DC counterpart in the intestine, based on their dependence on Batf3 and 
IRF8 and similar genetic profiles (25). Although their function in the intestine is still unclear, they 
may play a similar function as splenic CD8+ DCs in the cross-presentation of antigen.  
 
 
       
 
Adapted from Varol et al., Nat Rev Immunol (118) 
 
Figure 26. Dendritic cells of the intestinal lamina propria. Classical DC 
precursors give rise to the migrating DC subsets, CD103+CD11b- (red) and 
CD103+CD11b+ (orange) DCs. Resident CD11b+ CD103- CX3CR1+ DCs sample 






Notch signaling plays a pivotal role in multiple cell fate decisions, including immune cell 
differentiation. In mammals, there are five Notch ligands (Jagged1, Jagged2, Delta-like1, Delta-
like3, and Delta-like4) and four Notch receptors. Knockouts of Notch1 or Notch2 are 
embryonically lethal, as both receptors have known non-redundant roles in immune cell 
development. Notch3 and Notch4 knockout mice are fertile and overtly normal (119, 120). Both 
Notch3 and Notch4 lack the transactivation domain that is important for inducing transcriptional 
activity. The binding of a ligand to the Notch receptor releases the intracellular domain of Notch 
(NICD). The NICD translocates to the nucleus and binds to the transcription factor RBP-J (CSL) 
and co-activators, including the mastermind-like (MAML) family of transcriptional co-activators 
(Fig. 27). This leads to the displacement of co-repressors and expression of target genes, 
including a set of canonical Notch target genes, including Hes1 and Deltex1. The specificity of 
Notch signaling arises from receptor expression, post-translational modifications of the Notch 
receptor by Fringe glycosyl transferases, and the availability and preference for ligands and co-
activators (121).  
  One of the most well studied roles for Notch signaling is in the regulation of multiple stages 
of T cell development. Disruptions in Notch signaling, including naturally occurring Notch1 
mutations found in T-ALL patients, radically alter the T cell compartment (122). Deletion of 
Notch1 results in a complete block of T cell development (123) while constitutively active forms of 
Notch1 cause ectopic and excessive proliferation of T cells (124). Notch signaling also controls 
the αβ versus γδ T cell fate choice (125) and is required for pre-Tα expression during T cell 
commitment (126). Notch signaling also has a defined role in the differentiation of marginal zone 
versus follicular B cells in the spleen (127). However, unlike early T cell development in the 
thymus, this process is completely dependent on signaling through the Notch2 receptor (121). In 
addition to its role in regulating cell fate decisions, Notch signaling is also involved in TLR-
induced Jagged1 expression and the subsequent autoamplifying loop that leads to cytokine 
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secretion in macrophages (128). Therefore, Notch signaling not only directs binary cell fate 
decisions, but may also modulate cellular responses to TLR signals.    
   Here we show that signaling through Notch2 regulates a critical cell fate choice for DCs in 
the spleen and intestine. We have previously shown that Notch signaling plays an important role 
in maintaining CD11b+ DCs, and now demonstrate that the partial loss of CD11b+ DCs originally 
observed in the absence of Notch signaling results from the complete loss of a Notch-dependent 
subset within a heterogeneous pool of CD11b+ DCs. We further show that this Notch-dependent 
CD11b+ subset distinguishes not only a divergent developmental fate but also a functionally 
distinct cell type.  
         
      Adapted from Bray, et al. Nat Rev Mol Cell Bio 2006 (129) 
Figure 27. Notch signaling. Ligation results in successive cleavage of the Notch 
receptor, releasing its intracellular domain (NICD), which then translocates to the 




Notch2 signaling is required for splenic DC development. 
Caton et al. have previously shown that DC-specific inactivation of Notch signaling 
through CD11c-Cre-mediated targeting of RBP-J (DC-RBP-JΔ) leads to a partial depletion of 
CD11b+ DCs in the spleen (10). To further understand this activity, we tested the specific receptor 
requirements for Notch signaling in DCs. Since marginal zone B cells in the spleen selectively 
depend on signaling through Notch2 and thymocyte development is regulated through Notch1, 
both Notch1 and Notch2 receptors were targeted using CD11c-Cre-mediated conditional deletion. 
Only deletion of Notch2 (DC-Notch2Δ) was found to significantly affect the fraction and numbers 
of DCs within the spleen, whereas deletion of Notch1 had no effect on total splenic DCs (Fig. 
28A, B). Mice that conditionally express a dominant negative form of Mastermind-like1 protein 
(DNMAML) fused to GFP in the presence of CD11c-Cre were also analyzed to confirm the RBP-J 
deletion phenotype (DC-DNMAML). DNMAML mice had significant loss of DC fractions and 
absolute numbers in comparison to Cre-negative control, confirming that canonical Notch 
signaling was required for the observed phenotype (Fig. 29A, B).  
 Analysis of splenic DC subsets further confirmed that deletion of Notch2, but not Notch1, 
significantly diminished the fractions and absolute cell numbers of CD11b+ DCs (Fig. 29A, B). 
However, in contrast to the selective effect on CD11b+ DCs that was observed in RBP-J CKOs, 
the CD8+ DC population was also significantly reduced in the absence of Notch2 or presence of 
DNMAML (Fig. 29A, B). Abrogation of Notch signaling did not affect splenic PDC despite efficient 
Cre-mediated recombination in these cells as measured by GFP expression in DNMAML mice 
(Fig. 30 A-C). Nor did DC-specific targeting of Notch2 or DNMAML expression affect marginal 
zone B cell development (Fig. 31 A-C). DNMAML expression was specific to DCs; CD11b+ and 
CD8+ DCs expressed uniformly high levels of GFP, while pre-DCs were heterogeneously GFP-
positive (Fig. 32). Although a small percentage of follicular B cells expressed GFP, recombination 
was primarily excluded from marginal zone B cells, T cells and Cre-negative dendritic cells (Fig. 
32).  
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Deletion of Notch2 or expression of DNMAML also led to the accumulation of a CD11b-
CD8-, “double-negative” population within the CD11chi MHC class II+ subgate (Fig. 29A). This 
population was identified at low numbers in control spleens and was found to co-stain for either 
SIRPα or CD24, indicating that these cells could represent immature states of CD11b+ or CD8+ 
DC, respectively (Fig. 33B). In contrast, pre-DCs, identified as Flt3+ SIRPαlo-int, appeared 
unaffected by Notch2 targeting, indicating that signaling through Notch2 is not required for pre-
DC development, but is required for the transition into fully differentiated CD11b+ or CD8+ DCs 
(Fig. 33A). In addition to the loss of CD11b+ DCs, alterations in the surface phenotype of the 
remaining CD11b+ DCs were observed. Residual CD11b+ DCs in the Notch2 CKOs had markedly 
reduced surface staining of CD4 and DCir2, overall lower and less uniform levels of SIRPα, and 
elevated levels of CD11b (Fig. 33C). 
Due to the phenotypic abnormalities observed in the residual CD11b+ DC population, we 
speculated that CD11b+ DCs represented a heterogeneous population of cells that included a 
subset that was dependent on signaling through Notch2 and a Notch-independent subset. This 
hypothesis was supported by the observation of distinct GFPhi and GFPlo populations of CD11b+ 
DCs in Cx3cr1-GFP reporter mice, which have been used previously to distinguish DC subsets 
within intestinal and splenic CD8+ DCs (15). To determine if either the GFPhi or GFPlo CD11b+ DC 
populations in Cx3cr1-GFP mice was dependent on Notch signaling, Cx3cr-GFP+ DC-RBP-JΔ 
mice were analyzed. In the absence of Notch signaling, the residual CD11b+ DCs were uniformly 
GFPhi, indicating that the GFPlo population was dependent on Notch signaling (Fig. 34A).  
To identify markers that could be used to further distinguish these two subsets, CD11b+ 
DCs from RBP-J CKO and control animals were sorted and their expression profiles were 
compared. This led to the identification of Esam, an endothelial cell marker, as a demarking 
surface molecule of the GFPlo Notch-dependent subset. Among dendritic cells, Esam was most 
highly expressed on CD11b+ DCs and expressed at lower levels on CD8- DC, but not present on 
other splenocytes (Fig. 35A). Esamhi CD11b+ DCs were found to be virtually absent in DC-
Notch2Δ, DC-RBP-JΔ, and DC-DNMAML mice (Fig. 34B, 34D). In contrast, the percent and cell 
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numbers of Esamlo cells were not affected by the loss of Notch signaling (Fig. 34B, 34D). Esam 
levels were not significantly altered in Notch2-deficient CD8+ DCs (Fig. 35B).  
Mice that constitutively express the Notch1 intracellular domain (NICD) after Cre-
mediated recombination were crossed to the CD11c-Cre strain (DC-NICD) to determine if 
constitutive Notch activation could influence the development of Esamhi versus Esamlo CD11b+ 
DCs. Although their extracellular, ligand-binding domains vary, the intracellular domains of Notch 
receptors share significant homology. The fraction of CD11b+ and CD8+ DCs did not vary 
between DC-NICD and Cre-negative control mice. However, CD11b+ DCs were almost entirely 
Esamhi and did not express Clec12a, a marker that is preferentially expressed on the Esamlo 
subset (Fig. 34C, 36A, 36B). The enforcement of Notch signaling also induced Esam expression 
in CD8+ DCs, but not other splenocytes indicating that Esam is a target of Notch signaling in 
dendritic cells (Fig. 36B).  
 
Esamhi CD11b+ cDCs are Flt3 and lymphotoxinβ  receptor dependent.  
Flt3-, lymphotoxinβ receptor- (LTβR), or IRF4-deficient mice were examined to determine 
if other signaling pathways known to inhibit CD11b+ DC development would preferentially affect 
Esamhi or Esamlo CD11b+ DCs. In comparison to wild-type controls, splenocytes from Flt3 
knockout mice exhibited a significant reduction in Esamhi cells (Fig. 37A, B). The partial 
phenotype observed in these mice is consistent with previous observations of incomplete 
blockade of Flt3L-dependent signaling in Flt3 knockout animals (130, 131). Flt3-deficiency had no 
effect on the Esamlo population. LTβR deletion resulted in significant loss of Esamhi cells with no 
effect on the Esamlo fraction, fully recapitulating the phenotype observed in the absence of 
Notch2. In contrast, DC-specific deletion of Irf4, a transcription factor shown to affect DC 
development, did not preferentially affect either subset (Fig. 37A, B). The requirement for LTβR 
signaling during Esamhi DC development was further examined by competitive reconstitution of 
recipient mice with wild-type and knockout donor bone marrow. The percentage of LTβR-/- cells 
that contributed to the Esamhi DC population was significantly lower than wild-type donors, but 
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substantial in comparison to straight knockouts (Fig. 37C). This suggested that LTβR signaling in 
non-hematopoietic cells contributed in part to the development of Esamhi CD11b+ DCs. These 
data show that Esamhi DCs are dependent on different developmental signals than Esamlo DCs.  
 
Esamhi and Esamlo CD11b+ DC subsets exhibit distinct phenotypes.  
The Esamhi CD11b+ DC subset does not express higher levels of either Notch2 or LTβR 
despite its dependence on signaling through these receptors (Fig. 38B, C). The Esamhi Cx3cr1-
GFPlo CD11b+ DC subset exhibits differential surface marker expression in comparison to Esamlo 
Cx3cr1-GFPhi cells, including slightly elevated CD11c, CD4, and Dcir2 levels, and slightly lower 
Flt3, Clec12a, and CD11b expression (Fig. 38A). In addition to differences in surface marker 
expression, morphological distinctions were observed by microscopy on sorted and Giemsa-
stained cytospin preparations. Esamhi CD11b+ DCs exhibited typical dendritic morphology with 
diffuse cytoplasmic “veils” and irregular nuclear staining. Esamlo cells had more compact nuclei 
and cytoplasm, but did not display the prominent cytoplasmic vesicles of splenic macrophages 
(Fig. 39)  
 To compare the turnover and proliferation rates of the two subsets, BrdU incorporation 
assays were conducted. A higher fraction of Esamhi DCs incorporated BrdU over two days of 
BrdU pulse than the Esamlo DCs, indicating that Esamhi cells turnover more rapidly (Fig. 40A). 
After a two-hour pulse, more Esamhi cells had also entered S phase suggesting that the Esamhi 
cells had a faster proliferation rate, although the contribution of progenitors cannot be accounted 
for in this experiment (Fig. 40B). Overall these data demonstrate that the Esamhi and Esamlo DC 
subsets represent intrinsically different cell types.  
 
Gene expression profiling reveals distinct signatures of CD11b+ DC subsets. 
Genome-wide expression analysis was performed on sorted splenic DCs from Cx3cr1-
GFP and Cx3cr1-GFP+ DC-RBP-JΔ mice. Unsupervised clustering of the expression profiles of 
each sorted cell type demonstrated the close relative similarity between the Esamlo GFPhi DCs 
and residual CD11b+ DCs isolated from DC-RBP-JΔ (Fig. 41A). Pairwise comparison of gene 
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expression intensity between the Esamhi and Esamlo subsets revealed a significant number of 
differentially expressed genes, including Esam and Clec12a, as expected. Interestingly, Cdkn1a 
(p21), a cell-cycle inhibitor, was more highly expressed in the Esamlo fraction, consistent with the 
lower proliferation rate observed in this subset (Fig. 41B). Gpr4, a gene encoding a G protein-
coupled receptor, was highly upregulated in the Esamhi fraction and was one of the most 
differentially expressed genes between the two subsets.  
To examine the differences in gene expression between the two subsets in greater detail, 
three groups of signature genes were derived by comparing expression data for splenic 
CD11b+CD4+ DCs, CD8+CD11b- DCs, and Ly6C+MHC class II+ blood monocytes in the Immgen 
database: genes that were found to be typically expressed in DCs, genes that were specifically 
expressed in CD11b+ DCs in comparison to CD8+ DCs, and genes that were specifically 
upregulated in monocytes. The relative expression of these three groups of genes was then 
examined in the Esamhi and Esamlo subsets (Fig. 41B). DC-specific genes were similarly 
expressed between the two subsets, indicating that both subsets aligned with the general DC 
expression profile. However, CD11b+ DC-specific genes, including the canonical Notch target 
gene Deltex1 (Dtx1), were more highly expressed in the Esamhi subset. In contrast, the Esamlo 
population expressed more genes that were typical of monocytes, including Lyz2 and Ccr2. 
Importantly, although Esamlo CD11b+ DCs expressed elevated levels of monocyte-specific genes, 
including those encoding CD36 and CD14 in comparison to Esamhi counterparts, they did not 
reach the levels found in true monocytes or macrophages, confirming their distinction as dendritic 
cells (Fig. 42A-C). 
 
Dual origins of splenic CD11b+ DCs 
CCR2-RFP mice were examined to confirm that CCR2 protein could be detected at 
higher levels in Clec12a+CD11b+ DCs. RFP was highly expressed within CD11c-CD11b+ 
monocytes and macrophages, as expected (Fig. 43A). CCR2-RFP was similarly expressed at a 
homogenously high level on Clec12a+CD11b+ DCs. In contrast, Clec12a-CD11b+ DCs displayed a 
broad range of lower RFP expression. To trace the history of lysozyme M expression, Lys2-Cre 
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mice were crossed to Rosa26-stopflox-EYFP reporter mice. As expected, approximately half of 
monocytes and macrophages expressed YFP (Fig. 43B). A significant proportion of Esamlo 
CD11b+ DCs were also YFP positive, while Esamhi CD11b+ DC were uniformly YFP-negative, 
indicating that they had no history of lysozyme M expression, and therefore did not arise from 
YFP+ Esamlo CD11b+ DCs. This, along with the presence of Esamlo CD11b+ DCs found in the 
absence of Esamhi CD11b+ DCs in Notch-deficient splenocytes, shows that each population 
develops independently rather than sequentially. Adoptive transfer experiments further 
demonstrated that Cx3cr1-GFPhi CD11b+ cells could arise from transferred MDPs, but not CDPs, 
whereas Cx3cr1-GFPlo CD11b+ DCs developed from either progenitor (Fig. 43C). These data 
indicate that the two specific CD11b+ DC subsets originated through two distinct pathways. 
 
Esamhi and Esamlo CD11b+ cDC populations respond differently to TLR stimulation. 
Expression analysis revealed preferential expression of many TLR and TLR-related 
genes in the Esamlo subset, including the TLR adaptor protein MyD88 and TLR9 co-receptor 
CD14 (Fig. 42B). To test their response to TLR stimulation, DC-enriched splenocytes were 
cultured for six hours with TLR9 agonist CpG-B and analyzed for TNFα or IL-12 production. 
Esamlo DCs produced more TNFα than Esamhi cells and much more IL-12 than either Esamhi 
cells or monocytes in response to CpG-B stimulation (Fig. 44A). Esamlo cells also produced 
slightly more TNFα in response to heat-killed Listeria monocytogenes (HKLM), a TLR2 stimulant 
(Fig. 44B). In addition to increased cytokine production, Esamlo DCs exhibited an enhanced 
response to TLR stimulation by upregulating the maturation marker CD40 to higher levels than 
Esamhi DCs (Fig. 44C).  
 
Defective in vivo CD4+ T cell priming in the absence of Esamhi CD11b+ DCs. 
To determine if both subsets similarly primed CD4+ T cells, Cx3cr1-GFP mice were 
injected with 10ug ovalbumin (OVA) protein. Esamlo and Esamhi subsets were sorted from 
splenocytes two hours after injection and cultured for 72 hours with CFSE-labeled CD4+ T cells 
enriched from the spleens of OT-II transgenic mice. Esamhi and Esamlo DCs induced equivalent T 
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cell proliferation as measured by CFSE dilution in vitro (Fig. 45A). Next, DC-enriched splenocytes 
from DC-RBP-JΔ or Cre-negative controls were incubated for 24 hours with either OVA protein or 
peptide prior to culture with CFSE-labeled OT-II cells. In vitro T cell proliferation was normal even 
in the absence of Esamhi DCs (Fig. 45B). However, in vivo T cell priming was impaired in the 
absence of Esamhi DCs (Fig. 45C). CFSE-labeled OT-II cells were transferred into DC-RBP-JΔ or 
Cre-negative control mice and immunized with OVA 24 hours after transfer. Most of the T cells 
transferred to control animals divided within 72 hours, but DC-RBP-JΔ mice lacking the Esamhi 
subset were unable to efficiently induce T cell proliferation. This deficiency was not due to 
differences in the ability of either subset to phagocytose antigen, since this capacity, as measured 
by the uptake of FITC-labeled latex beads, was equivalent between Esamhi and Esamlo DCs (Fig. 
46).  
 
Notch2 controls the development of intestinal CD103+CD11b+ DC.  
We wondered if genetic and functional counterparts in peripheral tissues could be 
identified despite the lack of definitive Esam expression on DCs outside of the spleen. Since Gpr4 
is one of the most highly upregulated genes in the Esamhi subset by microarray, we analyzed 
Gpr4-GFP mice to determine if Gpr4 expression could distinguish Esamhi -like DCs in the 
intestinal lamina propria. GFP expression was distinctly expressed in CD8+ DCs and the Esamhi 
subset of CD11b+ DCs in the spleen and similarly detected in the intestinal CD8+ DC counterpart 
(Fig. 47A, B), CD103+CD11b-, and CD11b+CD103+ DCs in the small intestine, suggesting a 
similarity between CD11b+CD103+ and Esamhi DCs. 
 
Absence of intestinal CD103+CD11b+ DC leads to loss of Th17 cell potential. 
 The intestinal DCs of DC-Notch2Δ	
 animals were analyzed to determine if CD11b+CD103+ 
DCs were similarly dependent on Notch signaling. In comparison with Cre-negative littermate 
controls, there was a significant decrease in the percent and absolute cell numbers of 
CD11b+CD103+ DCs in Notch2-deficient mice (Fig. 48A, B). CD11b+CD103+ DCs were also 
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markedly reduced in the MLN (Fig. 48C). The loss of CD11b+CD103+ DCs led to a reduction in 




A novel Notch-dependent splenic DC subset 
Here we identify a novel Notch-dependent subset of CD11b+ DCs in the spleen. We have 
previously shown that Notch signaling plays an important role in maintaining splenic CD11b+ 
DCs, and now demonstrate that the partial lack of CD11b+ DCs originally observed in the 
absence of RBP-J results from the complete loss of a Notch-dependent subset within a 
heterogeneous pool of CD11b+ DCs in the spleen. These Notch-dependent CD11b+ DCs can be 
distinguished by their higher expression of Esam and lower level of Clec12a in comparison to 
Notch-independent CD11b+ DCs. 
   The endothelial cell surface adhesion molecule, Esam, was identified as a marker of 
active Notch signaling within DCs, and used to distinguish the Notch-dependent subset of DCs. 
Esam is an adhesion molecule that has been shown to be involved in neutrophil extravasation, 
but its role on DCs has never been examined. Esamhi DCs were found to exhibit a genetic profile 
typical of conventional CD11b+ DCs, while Esamlo DCs expressed many of the hallmark genes of 
monocytes and macrophages, albeit at much lower levels. Previous studies of DC subsets have 
often characterized DCs by CD4 expression. However, unlike Esam expression on CD11b+ DCs, 
CD4 expression does not clearly distinguish functionally distinct subsets. CD4 is more highly 
expressed on the Esamhi CD11b+ DC subset, but its expression overlaps considerably between 
the two subsets.  Consistent with their genetic profiles, Esamhi CD11b+ DCs were highly proficient 
at stimulating T cell proliferation, while Esamlo CD11b+ DCs demonstrated superior cytokine 
secretion in response to stimulation. Therefore, Esamhi and Esamlo CD11b+ DCs represent two 
functionally distinct subsets of CD11b+ DCs. 
  
Notch2 and lymphotoxinβ  are indispensible for Esamhi DC development 
   The Notch2 receptor is specifically required for Esamhi CD11b+ DC development while 
the Notch1 receptor is completely dispensable for DC development in the steady-state, in 
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contrast to previous claims (132). Notch3 is largely nonfunctional and is not expressed on DCs, 
and previous work has shown that Notch4 is dispensable for DC development. Similarly strict 
dependence on Notch2 has been reported in the generation of marginal zone B cells in the 
spleen. Delta-like1, has been identified as the ligand required for Notch2 activation in MZ B cells 
(133), but the precise ligand required for Notch2 signaling in DCs remains unknown. Given their 
similar localization, MZ B cells and CD11b+ DCs may share a common ligand source, but recent 
work has suggested that multiple ligands may be contribute to specifying the CD11b+ DC cell fate 
(134).  
  The involvement of both Notch2 and LTβR in splenic Esamhi DC development suggests 
that they share similar developmental cues with MZ B cells. In fact, preliminary work has 
suggested that Esamhi DCs similarly localized to the marginal zone (Fig. 50). It is tempting to 
speculate that Esamhi DCs and MZ B cells interact given their potentially shared developmental 
cues and localization. Although the absence of Notch-dependent DCs does not affect MZ B cell 
development (Fig. 31) or MZ B cell-dependent immune responses to S. pneumoniae, the 
interaction between Esamhi DCs and MZ B cells remains an open area of investigation. 
  An interesting outcome of this research is the identification of a population of CD11b-CD8- 
DCs in both Notch2-deficient and control mice. These cells appear to represent immature but 
committed CD11b+ and CD8+ DC precursors since they express either Sirpα or CD24, markers 
that are associated with CD11b+ or CD8+ DCs, respectively. Another intriguing finding is that 
targeting of RBP-J or expression of DNMAML does not appear to fully recapitulate the Notch2 
deletion phenotype. Although not previously described in mammalian systems, this result could 
suggest that additional non-canonical, or RBP-J independent, signaling could contribute to DC 
development. However, additional factors, including differences in strain background or the 
kinetics of different signaling component deletion could also explain this discrepancy.  
  LTβR deletion fully recapitulated the Notch2 deletion phenotype. Little is know about the 
potential interactions between the Notch and lymphotoxinβ signaling pathways. Since Esamhi 
DCs were less dramatically reduced in LTβR-/- bone marrow reconstitution experiments, it is likely 
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that LTβR deletion within non-hematopoietic splenic cells also affects Esamhi DC differentiation. 
In fact, LTβR deletion affects the development of normal splenic architecture, including the 
marginal zone, which is perhaps necessary for efficient Esamhi DC differentiation (135). Additional 
studies are necessary to validate this hypothesis.   
            
    
                                                                           Caton, et al. J Exp Med 2007 (10) 
 
Figure 50. Notch-dependent CD11b+ DCs are found in the marginal zone of 
the spleen. Localization of CD11b+ DCs (33D1+, red) in the marginal zone of the 
spleen in mice with DC-specific deletion of RBP-J (CKO) compared to Cre-
negative control. Staining for MOMA-1 on MZ metallophilic macrophages 
delineates the marginal zone (green).  
 
The dual origin of and division of labor between DC subsets 
  We show that signaling through Notch2 regulates critical cell fate choices for DCs and that 
Notch-dependent CD11b+ DCs represent functionally distinct cell types. Whereas the Esamlo 
Notch-independent CD11b+ DCs respond more robustly to TLR stimulation, the Esamhi Notch-
dependent subset appears more specialized at the presentation of antigen. This apparent 
“division of labor” in the spleen echoes a phenomenon that has been described in the intestine 
(136). CD103+CD11b+ intestinal DCs migrate to the MLN where they efficiently present antigen, 
while CD11b+CD103- DCs reside continuously in the intestinal LP and are specialized in secreting 
Ctrl CKO 
33D1  MOMA-1 
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the inflammatory cytokines that recruit and activate local immune cells. We demonstrate that 
Notch2 signaling is also critical for the development of the CD103+CD11b+ DC subset in the 
intestinal lamina propria. This is in contrast to CD103-CD11b+ DCs, which are Notch2-
independent. Therefore, Notch2 controls the development of the main antigen-presenting subsets 
of CD11b+ DCs in the spleen and intestine (Fig. 51).  
 
                               Lewis et al. Immunity 2011 (137) 
  
Figure 51. Signaling through the Notch2 receptor controls the 
differentiation of intestinal CD103+CD11b+ DCs and a novel subset of 
splenic CD11b+ DCs.  
 
 
  We also demonstrate that steady-state splenic DCs, like intestinal DCs, arise through two 
different pathways. Esamhi CD11b+ DCs develop from conventional DC precursors (preDCs), but 
Esamlo CD11b+ DCs originate from precursors of macrophages and DCs (MDPs). Conventional 
DC precursors similarly give rise to CD103+ DCs in the intestine, but not CD11b+ CD103- DCs 















Th17 cell differentiation 
Cytokine secretion 
Th cell expansion 
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Notch2 suggests that LP CD103+CD11b+ and splenic Esamhi CD11b+ DCs are related cell types. 
Further study of targets that are similarly expressed between these subsets in different tissues, 
such as Gpr4, may yield insights into their shared roles. Given the specific role of CD103+ DCs in 
migrating to the MLN, it will be interesting to determine if Esamhi CD11b+ also migrate within the 
spleen in response to antigen. However, better understanding of the steady-state localization of 
Esamhi CD11b+ DCs is necessary to begin to address this issue. 
  Another area for further investigation is to determine if Notch2 deletion affects DCs found in 
Peyer’s patches and isolated lymphoid follicles. We would also like to identify similar Notch2-
dependent DC subsets in other nonlymphoid tissues, such as the lung and liver. Although 
preliminary searches did not reveal similar Notch-dependent cell types, our analysis may have 
been hampered by the relative nescience of DC subsets outside of the spleen and intestine. It will 
also be important to determine if similar DC subsets can be identified in human organs. Recently, 
a human CD8+ DC equivalent was simultaneously identified by four groups, illustrating both the 
interest in finding human DC counterparts and the relative lack of understanding of human DC 
subsets (138-141).  
 
Notch2-dependent lamina propria DCs induce Th17 cells.  
  Our finding that selective depletion of CD103+CD11b+ DCs leads to loss of Th17 cells is 
consistent with previous research showing that CD103+CD11b+ DCs induce Th17 cells(142). In 
contrast, several studies have implicated CD103+CD11b+ DCs in the induction of Tregs and 
maintenance of oral tolerance (143, 144). Our data indicate that despite the loss of Th17 cells, 
Tregs are not concomitantly induced in the lamina propria or MLN. These results are unexpected 
since the current dogma predicts that loss of Th17 cells would lead to an expansion of Tregs. 
However, it is possible that when precisely challenged, differences in the Th17-Treg balance may 
be more apparent.  
  Another surprising finding was the number of Th17 cells found in control animals, which 
was much higher than expected. Previous research has shown that Th17 presence in the gut is 
directly influenced by colonizing intestinal microbiota (145). In particular, segmented filamentous 
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bacteria (SFB) have been shown to directly induce Th17 development. Although the mice used in 
this experiment tested negative for SFB, unidentified gut-colonizing microbes may have caused 
the elevated levels of Th17 cells observed in these animals.  
 
Targeting of Notch2-dependent lamina propria DCs. 
  In addition to their role in inducing Th17 cells, CD103+CD11b+ DCs have been reported to 
be important for the differentiation of IgA-secreting plasma cells and their retention in the gut 
(146). Our research represents the first demonstration of selective depletion of CD103+CD11b+ 
DCs from the LP. Further application of this model may yield insights into the possible roles of 
CD103+CD11b+ DCs in mucosal immunity, including the induction of oral tolerance and 
susceptibility to colitis and intestinal cancers. Depletion of total LP DCs did not increase 
susceptibility to colitis (136), but it remains unclear if disrupting the balance between DC subsets 
could influence inflammatory disease. It will be interesting to determine if disease outcomes can 
be altered through pharmacological manipulation of intestinal DC subsets. Recent efforts to treat 
T cell acute lymphoblastic leukemia (T-ALL) using γ-secretase inhibitors, which block Notch 
signaling, have been thwarted by significant gastrointestinal side effects (147). Preliminary 
experiments using a Notch2-specific antibody faithfully recapitulates our results in wild-type mice 
and presents a proof-of-principle that Notch2-specific antibody can be used to selectively target 
Esamhi CD11b+ and intestinal CD103+CD11b+ DCs. 
 
  The identification of two different subsets within the CD11b+ DC population, along with the 
recent finding of two different CD8+ DC subsets, reflects our expanding recognition of DC 
heterogeneity in the steady-state. This trend is most meaningful when phenotypic heterogeneity 
is indicative of true functional differences. Although lineage-tracing experiments suggest that 
there is little, if any, fluidity between these subsets in the steady-state, in remains unclear how 
strictly this heterogeneity is enforced, and to what degree it is maintained at the expense of 
plasticity of function, particularly during active immune responses. Finally, it will be important to 





Dendritic cell-specific deletion using the CD11c-Cre (Itgax-Cre) hemizygous transgene have been 
previously described (10). CD11c-Cre mice were crossed to animals carrying homozygous 
conditional alleles of Notch1 (121, 123), Notch2 (148), RBP-J (127), and IRF4 (123, 149) to 
generate DC-Notch1Δ	
, DC-Notch2Δ	
 (mixed B6/129), DC-RBP-JΔ	
, and DC-IRF4Δ	
 animals, 
respectively. Mice expressing a dominant negative form of Mastermind1 fused to GFP (Rosa26-
Stopflox-DNMAML, B6 or B6129F1) or overexpressing the Notch1 intracellular domain (Eef1a1-
Stopflox-NICD1, mixed B6/129) in the presence of Cre have been described previously (150). 
These mice were also crossed to CD11c-Cre deleter mice to abrogate (DC-DNMAML) or 
constitutively activate Notch signaling within DCs (DC-NICD). Cre-negative littermates were used 
as controls since CD11c-Cre does not affect DC numbers or phenotype (10).  
Reporter mice carrying the carrying an EGFP transgene that replaces the Cx3cr1 gene to 
generate homozygous Cx3cr1-GFP mice have been described previously (106). These mice 
were also bred to RBP-J and CD11c-cre mice to generate hemizygous GFP-positive, DC-RBP-JΔ	
 
animals and GFP-positive Cre-negative littermates. For Lyz2-Cre lineage tracing, Lyz2-Cre mice 
(151) were crossed to a reporter strain expressing EYFP upon Cre recombination 
(Gt(ROSA)26Sor-EYFP) to generate hemizygous Lyz2-Cre+ EYFP+ reporter mice (97). 
Heterozygous CCR2-RFP (152) and Gpr4-GFP (153) mice have been previously described.  
 Germline null mutants of Flt3 (131) and lymphotoxinβ receptor (12) have been described. 
LTβR-/- bone marrow chimeras were generated by the Gommerman lab by reconstitution of 
lethally-irradiated recipients with wild-type competitor and knockout donor cells at a 1:1 ratio, as 
previously described (131, 154). Chimeras were sacrificed 11 weeks after transfer, and spleens 
were shipped overnight on ice and analyzed in the Reizis lab. Donor- and competitor-derived 
cells were distinguished by differential CD45 isoform expression.  
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 For intestinal analyses, co-housed, sex-matched mice were used. All experimental mice 
were on a C57BL/6 (B6) background except where indicated otherwise. All animal work was 
performed according to protocols approved by the Columbia University Institutional Animal Care 
and Use Committee.  
 
Cell analysis 
Isolation and analyses of primary cells from lymphoid organs (7) (10) and intestinal lamina propria 
were performed as described (24, 98, 155). The biotin-conjugated anti-Clec12a antibody was a 
kind gift from Dr. M. Lahoud (Walter and Eliza Hall Institute). Samples were analyzed by flow 
cytometry using LSRII, sorted on a FACSAria flow sorter (BD Immunocytometry), and analyzed 
using FlowJo software (Tree Star, Inc.).  
 
Morphological analysis 
Sorted cells were prepared using a Cytospin 3 centrifuge (Thermo Shandon) and stained by 
Giemsa stain.  
 
In vitro cytokine production 
To measure cytokine production, splenocytes were lineage-depleted for B, T, NK, and erythroid 
cells by negative selection using MACS columns (Miltenyi). Approximately 106 DC-enriched 
splenocytes were incubated at 37°C with 100 nM CpG-B oligonucleotides (ODN1826), 108 heat-
killed Listeria monocytogenes (HKLM, Invivogen), or endotoxin-free water (Invivogen). After 2 
hours, Brefeldin A (5 μg/ml) was added and the cells were incubated for another 4 hours at 37°C. 
Cells were then surface-stained, fixed with Cytofix-Cytoperm (BD Biosciences) for 20 minutes, 
and then stained for intracellular cytokines by incubating in permeabilization buffer (2%FCS, 0.5% 
saponin in PBS) containing either APC-labeled anti-IL-12 or anti-TNFα  (BD Biosciences), 





DC maturation  
To evaluate DC maturation, splenocytes were enriched for DCs by negative selection using 
MACS columns (Miltenyi). Approximately 106 DC-enriched splenocytes were incubated at 37°C 
with 100 nM CpG-B oligonucleotides (ODN1826), 108 heat-killed Listeria monocytogenes (HKLM, 
Invivogen), or endotoxin-free water (Invivogen) for 24 hours and then analyzed by FACS for 
CD40 expression.  
 
BrdU incorporation 
Cx3cr1-GFP mice were either injected i.p. with 1.5 mg BrdU and analyzed after two hours or 
injected i.p. with 1.5 mg BrdU on two consecutive days and analyzed for BrdU incorporation 24 
hours after the last injection. BrdU staining was performed using an APC BrdU Flow Kit (BD 
Biosciences) and combined with DAPI for the two-hour pulse.  
 
Gene expression analysis 
Splenocytes from Cx3cr1-GFP+ DC-RBP-JΔ  mice or Cre-negative controls were depleted of 
lymphoid and erythroid cells by negative selection on MACS columns (Miltenyi) and sorted. Total 
RNA was isolated using RNeasy columns (Qiagen). Samples were then reverse-transcribed, 
labeled, and hybridized to GeneChip Mouse Gene 1.0 ST array (Affymetrix) according to 
manufacturer’s instructions. RMA-normalized gene expression values were analyzed using NIA 
Array software (156). The signatures of normal DC populations were derived by clustering 
analysis of Immgen subsets DC.4+.Sp, DC.8+.Sp and Mo.6c+II+.BI (157). Real-time quantitative 
PCR was performed as described (10). 
 
T cell proliferation assay 
CD4+ T cells from spleens and lymph nodes of OVA-specific OT-II transgenic mice (158) were 
enriched by negative selection using MACS columns (Miltenyi) and labeled with CFSE. For in 
vivo proliferation, 2 x 106 labeled T cells were injected i.v. into DC-RBP-JΔ  or Cre-negative 
control mice. After 24 hours, recipients were immunized with 10 mg ovalbumin (Sigma) i.v. and 
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analyzed 72 hours later. For in vitro proliferations, Cx3cr1-GFP mice were injected i.v. with 10 mg 
ovalbumin. After 2 hours, DC-enriched splenocytes were prepared by negative selection on 
MACS columns and plated at a 5:1 T to DC ratio with CFSE-labeled T cells. Cells were incubated 
for 72 hours and T cells were analyzed for CFSE dilution.  
 
Phagocytosis assay 
Wild-type (B6129F1) mice were injected with approximately 1010 FITC-labeled 0.5µm latex beads 
(Fluoresbrite Microparticles, Polysciences) and analyzed after 5 hours.  
 
MDP/CDP transfer 
Macrophage and DC progenitors (MDP) or common DC progenitors (CDP) were sorted from the 
bone marrow of Cx3cr1-GFP mice, transferred i.v. into naïve non-irradiated CD45.1 congenic 




All statistical analyses were performed with Prism 4.0 (Graphpad Software Inc.). Data were 
analyzed with the unpaired Student's t-test assuming that the values followed a Gaussian 

















Figure 28.  Notch2 signaling is required for splenic DC development.  
 
Conditional knockout animals (Cre+) with dendritic cell (DC)-specific deletions of Notch1 or 
Notch2, or DC-specific overexpression of a dominant negative form of Mastermind-like1 
(DNMAML) were analyzed in parallel to Cre-negative littermate controls (Cre-).  
(A) Representative staining profiles of splenic cells, with the percentages of CD11chi MHC cl. II+ 
cells highlighted. 
(B) Fraction (top) and absolute numbers (bottom) of DCs within total splenocytes. Statistically 
significant differences are indicated: ***, p < 0.001; **, p < 0.01; *, p < 0.05. 
 










































Figure 29.  Notch2 signaling affects CD11b+ and CD8+ DC development in the spleen.  
 
(A) Representative staining profiles and percentages of CD11b+ (blue), CD8+ (green), and 
double-negative cells (purple) within CD11chi MHC cl. II+ splenic DCs. The percentages represent 
a mean ± S.D. of 3-6 mice for Notch1 and Notch2, and 11-12 mice for DNMAML.  
(B) Percentage among splenocytes (top) and absolute number (bottom) of CD11b+ (left) and 
CD8+ (right) DCs (mean ± S.D. of 8-10 animals per genotype).  
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Figure 30.  DC-specific Notch2 deletion or signal disruption does not affect plasmacytoid 
dendritic cell development.  
 
(A) Representative staining profiles of splenocytes with DC-specific deletion of Notch2 (DC-
Notch2Δ) or expression of DNMAML (DC-DNMAML) compared to Cre-negative littermate 
controls, with fractions of CD11cint Bst2+ plasmacytoid dendritic cell (PDC) highlighted.  
(B) Fractions of PDCs within total splenocytes of indicated Cre+ and Cre- animals (mean ± S.D. of 
3-5 animals per genotype). Statistically significant differences are indicated: ***, p < 0.001; **, p < 
0.01; *, p < 0.05. 
(C) Histogram of GFP expression in PDCs from DC-DNMAML spleens with GFP-positive 





































Figure 31.  DC-specific Notch2 deletion or signal disruption does not affect marginal zone 
B cell development. 
 
(A) Representative staining profiles of splenocytes with DC-specific deletion of Notch2 (DC-
Notch2Δ) or expression of DNMAML (DC-DNMAML) compared to Cre-negative littermate 
controls, with the fractions of CD21hi CD23lo marginal zone (MZ) and CD21lo CD23hi follicular 
(FO) B cells among B220+CD93- cells indicated.  
(B) Fractions of MZ B cells within total splenocytes of Cre+ and Cre- animals (mean ± S.D. of 3-5 
animals per genotype). 
(C) Histogram of GFP expression by MZ B cells, FO B cells, or T cells in DC-DNMAML spleens 













































Figure 32.  CD11c-Cre-mediated DNMAML expression is specific to dendritic cells.  
 
Histograms of GFP fluorescence in the indicated splenic cell type, including CD11b+ and CD8+ 
CD11chi MHC cl. II+ DCs, CD11chi MHC cl. II+Flt3+ pre-DCs, and CD11chi MHC cl. II+ DCs from 
Cre-negative mice included as a negative control (control DC). 



















Figure 33.  Pre-DCs are not affected by DC-specific Notch2 deletion.  
 
Data generated by Kang Liu 
Mice with CD11c-Cre-mediated deletion of Notch2 (DC-Notch2Δ) were compared with Cre-
negative littermate controls (Ctrl).  
(A) Flt3+Sirpα- pre-DC populations in bone marrow and spleen of DC-Notch2Δ and control 
animals among on lineage-negative CD11chi MHC cl. II+ cells.  
(B) Sirpα and CD24 expression on double-negative splenic DCs that accumulate in Notch2-
deficient animals compared to controls, with percentages amongst preDCs indicated.   
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Figure 34.  Notch/RBP-J signaling specifies a distinct population of CD11b+ cDC. 
 
Expression of a Cx3cr1-GFP reporter in CD11chi MHC cl. II+ CD11b+ splenic DCs from DC-
specific deletion of RBP-J (DC-RBP-J Δ) was analyzed in parallel with Cx3cr1-GFP-positive, Cre-
negative littermate controls (Ctrl) (A-C).  
(A) Histogram of GFP expression in gated splenic CD11b+ DCs in control (red) and DC-RBP-JΔ 
(blue) mice.  
(B) Representative profiles of GFP vs. Esam expression on gated CD11b+ DC. 
(C) Representative profiles of Clec12a vs. Esam expression on gated CD11b+ DC. 
(D) Percentage (top) among total splenocytes and absolute number (bottom) of Esamhi (left) and 
Esamlo (right) CD11b+ DCs in mice with DC-specific targeting of Notch2 or RBP-J, or DC-specific 
overexpression of DNMAML compared to Cre-negative controls (mean ± S.D. of 3-5 animals per 












































































Figure 35.  Esam is highly expressed on CD11b+ DCs.  
 
(A) Esam expression on different splenocyte populations in Cx3cr1-GFP transgenic mice 
(B) Esam expression on CD11b+ and CD8+ DCs in DC-Notch2Δ or Cre-negative littermate 


























Figure 36.  Notch overexpression enforces Esamhi CD11b+ splenic DC development.  
 
Mice that overexpress the Notch1 intracellular domain in a DC-specific manner (DC-NICD) were 
compared to Cre-negative littermate controls (Ctrl). Representative of 8 animals per genotype.  
(A) Splenic DC populations in DC-NICD compared to control mice.  

































Figure 37.  Esamhi CD11b+ cDC development requires lymphotoxinβ  receptor signaling. 
 
Experimental animals (Expt) were compared to respective controls (Ctrl). Flt3 and lymphotoxinβ 
receptor (LTβR) knockout animals were analyzed in parallel with wild-type controls.  
(A) Representative profiles of CD11c versus Esam expression after gating on CD11b+ MHCII+ 
splenocytes are shown with percentages of Esamhi CD11b+ DCs highlighted. RBP-J-deficient 
(DC-RBP-JΔ) splenocytes that lack Esamhi CD11b+ DCs and Cre-negative littermate controls are 
included for comparison.  
(B) Percent of Esamhi (left) and Esamlo (right) CD11b+ cDCs within the spleens of Flt3 and LTβR 
knockouts compared to respective controls (Ctrl). Mice with CD11c-cre-mediated IRF4 deletion 
were analyzed in parallel with Cre-negative littermate controls (Ctrl) (mean ± S.D. of 4-5 animals).  
 
Chimeras were made by Dennis Ng (C, D) 
(C) Splenic Esamhi CD11b+ population among gated wild-type competitor (WT) or LTβR-/- donor 
populations in competitively reconstituted bone marrow chimeras (mean ± S.D. of 3 animals).  
(D) Fraction of wild-type competitor or LTβR-/- donor-derived CD11b+ DCs among total 
splenocytes in BM chimeras (mean ± S.D. of 3 animals).  





































































Figure 38.  Surface marker and receptor expression of CD11b+ DC subsets.  
 
Phenotypic analyses were performed using splenocytes from Cx3cr1-GFP transgenic mice to 
distinguish Esamhi GFPlo and Esamlo GFPhi CD11b+ DCs.  
(A) Histograms of indicated marker expression in Esamhi (blue) and Esamlo (red) CD11b+ cDC. 
Dashed line indicates positive staining threshold. 
(B) Level of lymphotoxinβ receptor expression on DC subsets.  
(C) Expression of Notch receptors in sorted CD11b+ DC subsets normalized to the Esamhi sample 
as determined by quantitative PCR (mean ± S.D. of triplicate samples). 
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Figure 39.  CD11b+ DC subsets exhibit distinct morphology.  
 
Microphotographs of sorted Esamhi and Esamlo CD11b+ DC and macrophages (Mφ) after cytospin 





Figure 40.  Esamhi CD11b+ DCs proliferate more rapidly than Esamlo CD11b+ DCs.  
 
(A) Histogram of BrdU staining in GFPhi (red) and GFPlo (blue) CD11b+ DC after 2 days of in vivo 
BrdU pulse. Shown are percent of BrdU-positive cells within indicated subsets (representative of 
4 animals).  
(B) Cell cycle profiles of DC subsets 2 hours after in vivo BrdU pulse. Fractions of cells in S and 






















Figure 41.  Gene expression profiles of splenic CD11b+ DC subsets. 
 
Gene expression profiles were generated from microarray analysis of sorted splenic Esamhi GFPlo 
and Esamlo GFPhi CD11b+ DCs isolated from Cx3cr1-GFP reporter mice and sorted splenic 
Esamlo GFPhi CD11b+ DCs from Cx3cr1-GFP+ DC-RBP-J Δ animals 
(A) Unsupervised clustering analysis of expression profiles of CD11b+ DC subsets.  
(B) Pairwise comparison of Esamhi and Esamlo gene sets. Probes with more than two-fold 
overexpression in Esamlo (red) or Esamhi (green), and probes for relevant genes (blue) are 
highlighted. Signature genes of total DCs (top right), CD11b+ DCs (bottom left), and monocytes 
(bottom right) were derived from the Immgene database and plotted to compare their relative 



































































Figure 42. Esamlo CD11b+ DCs preferentially express myeloid genes, but at a lower level 
than monocytes and macrophages.  
 
Gene expression analysis was determined by quantitative PCR on sorted Esamhi and Esamlo 
CD11b+ DC subsets and CD11b+F4/80+ macrophages from spleens of Cx3cr1-GFP mice. Data 
were normalized relative to the level of expression in the Esamhi sample (mean ± S.D. of triplicate 
samples).  
(A) Colony stimulating factor receptor (Csfr) expression in DCs or macrophages. 
(B) Differential expression of indicated genes between Esamhi and Esamlo DC subsets. The 
expression level of the canonical Notch target, Deltex1 (Dtx1), is included as a control.  
(C) Differential gene expression of DC subsets in comparison with macrophages. Data are shown 

















































































Figure 43.  Esamlo/Clec12ahi CD11b+ DCs express CCR2 and LyzM-expressing and do not 
arise from transferred CDPs.  
 
(A) Histograms of RFP expression by different splenocyte populations of Ccr2-RFP mice. CD11b+ 
CD11c- monocytes and macrophages (Mo/Mφ), Clec12a- CD11b+ DCs (corresponding to the 
Esamhi subset) and Clec12a+ CD11b+ DCs (corresponding to the Esamlo subset) are included.  
(B) Lyz2-Cre-mediated recombination in different splenic cell types as measured by YFP 
fluorescence from Lyz2-Cre+ mice with a Cre-inducible EYFP reporter (Rosa26-stopflox-EYFP).  
(C) Experiment performed by Kang Liu. 
Derivation of GFPhi and GFPlo CD11b+ DCs from transferred macrophage/DC progenitors (MDPs) 
or common DC progenitors (CDPs). MDPs or CDPs were sorted from the bone marrow of 
Cx3cr1-GFP reporter mice (CD45.2), transferred into naïve CD45.1 congenic mice, and analyzed 



































Figure 44.  Esamhi and Esamlo CD11b+ cDC populations respond differently to TLR 
stimulation. 
 
(A) Cytokine production by CD11b+ DCs in vitro. Lymphocyte-depleted splenocytes from Cx3cr1-
GFP transgenic mice were stained for TNFα or IL-12 after incubation with the TLR9 ligand CpG-B 
or LPS-free water for 6 hours. Percentages of TNFα+ or IL-12+ cells are highlighted. 
Representative of three experiments.  
(B) TNFα production in response to different TLR ligands in vitro. Splenocytes were prepared as 
above and stained for TNFα after treatment with LPS-free water, CpG-B, or heat-killed Listeria 
monocytogenes (HKLM) for 6 hours. The fractions of TNFα+ cells are indicated.  
(C) Phenotypic maturation of CD11b+ DCs in vitro. Splenocytes were prepared and stimulated as 
above, and stained for DC maturation marker CD40. Mean fluorescence intensities (MFI) are 
indicated. 
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Figure 45.  Defective CD4+ T cell priming in the absence of Esamhi CD11b+ DCs. 
 
CD4+ T cells were enriched from spleens and LN of OT-II OVA-specific TCR transgenic mice, 
labeled with CFSE and co-cultured with indicated cells.  
(A) In vitro T cell priming by Esamhi and Esamlo CD11b+ DCs. T cell proliferation, as measured by 
CFSE dilution, after co-culture for 72 hours with sorted subsets from Cx3cr1-GFP reporter mice 
that were injected i.v. 2 hours prior with 10 µg OVA protein. Black line indicates CFSE dilution by 
T cells incubated with total DCs isolated from control saline-injected mice. 
 
Data generated by Michele Caton (B, C) 
(B) In vitro T cell priming in the absence of Esamhi DCs. Splenic CD11chi DCs were enriched by 
positive selection from DC-RBP-JΔ or Cre-negative control mice and incubated for 24 hr with 125 
ng/ml ovalbumin (OVA) or 1.7 µg/ml OVA peptide 323-339 prior to co-culture.  
 (C) In vivo T cell priming in the absence of Esamhi DCs. CFSE-labeled OT-II cells were 
transferred to DC-RBP-JΔ or Cre-negative control mice, immunized with OVA 24 hours after 
transfer, and analyzed 3 days after immunization. The fractions of T cells that did not divide, 
























Figure 46.  Antigen uptake of CD11b+ DC subsets 
 
Uptake of FITC-labeled latex beads by splenic cell types was measured through analysis 5 hours 
after injection of wild-type C57BL/6 mice with 1010 beads. Fractions of FITC+ cells are indicated. 
Representative of 3 animals.  
 
















Figure 47. Gpr4 is expressed preferentially on Esamhi CD11b+ splenic DCs and 
CD103+CD11b+ intestinal DCs 
 
Histograms of GFP fluorescence by indicated splenic (A) and intestinal DC (B) subtypes isolated 
from Gpr4-GFP (red) and GFP-negative littermates (blue). Representative of 2 mice 
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Figure 48.  Notch2 controls the development of intestinal CD103+CD11b+ DC. 
 
Data generated by Milena Bogunovic. 
(A). Staining profiles of intestinal lamina propria DC cell populations in mice with DC-specific 
deletion of Notch2 (DC-Notch2Δ) in comparison with Cre-negative littermate controls (Ctrl). Gated 
CD45+ CD11chi MHC II+ cells are shown (left), and the CD11b+ subset is further analyzed with the 
CD11b+ CD103+ F4/80- population highlighted (right). (mean ± S.D. of 4 animals per genotype). 
(B) Absolute numbers of intestinal DCs in DC-Notch2Δ and Cre-negative littermate controls 
(mean ± S.D. of 4 animals per genotype).  
(C) Staining profiles of CD11chi MHC II+ cells isolated from the mesenteric lymph nodes in DCs in 
DC-Notch2Δ and Cre-negative littermate controls. Fractions represent mean ± S.D. of 7 animals) 




















































































Figure 49.  Absence of intestinal CD103+CD11b+ DC leads to Th17 cell loss.  
 
Data generated by Ivaylo Ivanov. 
Effector T cell populations in the lamina propria (LP) of the small intestine were analyzed  
(A) Staining profiles of gated CD11chi MHC II+ cells from intestinal LP of DC-Notch2Δ  and Cre-
negative controls. Fractions of each DC subset are indicated.  
(B) Staining profiles of gated TCRβ+ CD4+ T cells. Fractions of FoxP3+ regulatory T cells are 
indicated.  
(C) Staining profiles of gated TCRβ+ CD4+ T cells 4–5 hours after stimulation with PMA and 
ionomycin. Fractions of IL-17-producing Th17 cells are highlighted. (Two pairs of littermates are 











































Functional definition of PDCs  
  The generation of a model of complete peripheral PDC deletion has led to the discovery of 
a novel role of PDCs in controlling chronic viral infections. Further application of this model may 
yield additional insights into the role of PDCs in autoimmunity, tolerance, and cancer. These 
studies will help to resolve some of the outstanding questions about the role of PDCs beyond viral 
infection and establish a functional definition of PDCs.  
  Deletion of E2-2 was found to ablate PDCs in every organ examined. PDCs were readily 
identified in different tissues by their consistent phenotype as CD11cint Bst2+ B220+ CD11b- cells. 
Conventional DCs, on the other hand, exhibited distinct phenotypes in the different organs, which 
may reflect particular adaptations to their tissues of residence. A key difference between cDCs 
and PDCs is that PDCs develop completely in the bone marrow, whereas cDCs differentiate in 
the periphery. Tissue-specific adaptations of PDCs may be less obvious because PDCs adopt 
their fate within the bone marrow and may be less sensitive to developmental cues in the 
periphery. Since peripheral PDCs appear to be phenotypically similar throughout different tissues, 
it is possible that they are also uniform in function. However, further study may also reveal 
presently unappreciated differences between PDCs in different tissues.  
 
The role of E2-2  
  Preliminary studies of E2-2 in autoimmune diseases have revealed a striking link between 
the E2-2 expression and the severity of lupus-like disease. Deficiency in E2-2 expression appears 
to confer resistance to disease, which suggests a disease-enhancing role for PDCs in SLE. Initial 
studies have also led to the speculation that TCF4 may be a gene involved in the SLE 
susceptibility associated with the 18q21 locus. We are currently testing this hypothesis in other 
SLE and autoimmune disease models.  
  The identification of an E protein as a master regulator of the PDC lineage has helped to 
explain the genetic link between lymphocytes. However, the expression of E2-2 in the brain and 
its involvement in diseases like Pitt-Hopkins syndrome and schizophrenia remain a mystery. E2-2 
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is the only E protein that is expressed significantly in the mouse and human brain. Just as 
identification of common E2-2 targets between lymphocytes and PDCs has helped to reveal the 
nature of PDCs, comparison of common targets in the brain and PDCs may help to elucidate 
mechanisms involved in these diseases. 
 
DCs in intestinal immunity 
   The depletion models generated in these studies may help to uncover the function of 
CD103+CD11b+ DCs and PDCs in intestinal immune homeostasis. In particular, the role of 
CD103+CD11b+ intestinal DCs in the generation of Th17 and regulatory T cells will be further 
investigated. Preliminary results using pharmacological inhibition of Notch2 signaling have 
already demonstrated that depletion of CD103+CD11b+ DC is possible by administration of an 
anti-Notch2 antibody. This approach will be extended to determine if CD103+CD11b+ DC 
reduction leads to impaired Th17 responses. These studies, along with research using Batf3 
knockout mice, which selectively depletes CD103+CD11b- DCs in the intestine, will advance our 
understanding of the contribution of different DC subsets in intestinal immunity. Preliminary 
studies have demonstrated the absence of intestinal PDCs in conditionally targeted E2-2 mice 
(Fig. 15). Although the role of PDCs in intestinal immunity remains largely unknown, one study 
identified PDCs as mediators of oral tolerance (82). We aim to test this function using PDC-less 
mice. In addition, we also plan to investigate the involvement of PDCs and CD103+CD11b+ in 
chronic inflammation and gastrointestinal cancers.  
 
Human DCs 
  A major goal for future research will be to apply the knowledge of murine DC biology to 
humans. Relatively little is known about DC subsets in humans. Until recently, only PDCs and 
CD11b+ “myeloid” DCs (mDC) had been isolated from human samples. The identification of a 
cross-presenting CD8+ DC equivalent in humans has helped to demonstrate that subset 
specifications identified in mice may also exist in humans (138-141). Furthermore, the 
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observation that the E2-2 insufficiency that causes Pitt Hopkins syndrome (PHS) also leads to 
impaired PDC function in PHS patients indicates that critical regulators of DCs may be conserved 
between species. We are currently developing techniques to isolate DCs from human tissue 
samples in order to determine if DC subsets similar to those identified in this study can be found 
in humans.  
 
Understanding DC subsets 
A clearer picture of DC subsets and their functions has begun to emerge through the 
identification of specific transcription factors and signaling pathways that specify distinct lineages 
in the spleen and nonlymphoid organs. Edelson et al. have shown that Batf3 controls the 
differentiation of CD8+ DCs in the spleen and CD103+ CD11b- DCs in the intestine (25). Now we 
have found that signaling through Notch2 regulates critical steps in the differentiation of splenic 
CD11b+ DCs and intestinal CD11b+CD103+ DCs. We have also demonstrated that E2-2 controls 
the differentiation and maintenance of PDCs in all tissues. Through conditional targeting of these 
specific cell types, we have also identified minor populations that lie within the continuous 
spectrum that exists between subsets: PDC-like alternative CD8+ DCs and monocyte-like Esamlo 
CD11b+ DCs. Finally, by comparing the functional divergence of DCs in different organs, we have 
uncovered a remarkable symmetry in the division of labor between DC subsets in the spleen and 
intestine. The identification of specific developmental requirements of DCs has enabled the 
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